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CHAPTER 1 INTRODUCTION 
1.1 Cancer as a Disease 
Cancer is a group of diseases characterized by uncontrolled cell 
proliferation, resistance to cell death, evasion of immune system destruction, 
angiogenesis, invasion as well as metastasis1,2. Various genetic mutations in 
oncogenes or tumor suppressor genes together with many epigenetic factors such 
as changes in DNA methylation are considered as contributors to the disruption of 
cell signaling, cell growth, and cell proliferation control, which leads to 
tumorigenesis and cancer development3–7.  
Cancer is considered as a serious killer. According to the world health 
organization (WHO) 8.2 million individuals died from cancer in 2012 and the 
number of new cancer patients is expected to increase by around 70% in the 
coming 20 years. In the United States, cancer is the second leading cause of death 
just after the cardiovascular diseases as reported by the National Center for Health 
Statistics (NCHS) for the year 20148. American Cancer Society estimated that 
there will be 1,685,210 new cancer cases and 595,690 cancer deaths, in 2016 in 
USA alone9.  
Different therapeutic interventions are available to overcome cancer and 
increase patient’s survival rates. Among these, surgery and radiation therapy are 
the first line therapeutic strategies for cancer, however, for metastatic cancers they 
are not effective as standalone therapy. Chemotherapy, on the other hand, is one 
of the most commonly used therapeutic strategies to fight both local and metastatic 
cancers either alone or as adjuvant therapy10,11. However two major limitations for 
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cancer chemotherapeutic drugs are toxicity towards rapidly growing normal cells, 
as well as the emergence of multi drug resistance (MDR) mechanisms, leading to 
poor therapeutic outcomes1. 
1.2 Liver Cancer 
Liver cancer is a type of neoplasm that affects the hepatic tissues.  
According to WHO, liver cancer was the second  most common lethal cancer 
worldwide in 201212. In contrast to the declining trend among most cancer types, 
liver cancer showed increase in incidence and mortality rates, indicating its poor 
prognosis9,13. American cancer society, estimated 39,230 new cases of liver 
cancer to occur in the US during 2016, approximately three-fourths of which will 
be hepatocellular carcinoma (HCC)14.  
1.2.1 Hepatocellular Carcinoma Risk Factors 
Hepatocellular carcinoma is the most prevailing histological type of liver 
cancer15. It occurs mostly in inflamed and cirrhotic liver, with the most common 
causes being the Hepatitis B (HBV) and Hepatitis C (HCV) viral infections15,16. 
Other risk factors correlated with HCC are aflatoxin B1 ingestion, alcohol and 
tobacco consumption, non-alcoholic fatty liver disease, iron overload in 
hemochromatosis17 and type 2 diabetes18.  
1.2.2 Hepatocellular Carcinoma Therapeutic Strategies 
There are multiple treatment strategies for HCC depending on liver function, 
the tumor size, number of lesions and stage. Surgical liver resection to remove the 
tumor with some healthy tissues around it is mostly performed in case of non-
cirrhotic, single tumor lesion as opposed to the cases of cirrhosis or multiple 
3  
  
invasive tumor lesions. The latter cases are more susceptible to post resection 
recurrence of tumor19,20. Non-surgical but invasive therapeutic approaches include 
percutaneous ethanol injection (PEI)21, radiofrequency ablation (RFA)22, local 
radiotherapy (LR) and trans arterial chemoembolization (TACE)23, that are used 
for patients who are not candidates for resection. Liver transplantation is another 
therapeutic modality for HCC with limitations of being a big and expensive 
procedure. In addition it takes long time to find a well matched liver donor, and 
requires immunosuppressive treatment post operation to avoid new liver 
rejection19,24. Unfortunately, the majority of HCC patients (>80%) are diagnosed at 
an advanced stage where the above curative therapeutic options would not be 
effective25,26. Systemic chemotherapies such as cytotoxic drugs or antiangiogenic 
agents are mostly the treatment of choice for patients with advanced late stage 
HCC, in addition to their application as adjuvant therapies with other treatment 
options. Systemic cytotoxic small molecule treatments such as doxorubicin, 
epirubicin, cisplatin, 5-fluorouracil, etoposide and their combinations were used for 
advanced HCC, however very low efficacy with no more than 20% response rate 
was achieved25,26. On the other hand, newer therapies using sorafenib or erlotinib 
have demonstrated antiangiogenic activity as a result of being tyrosine kinase 
inhibitors. Bevacizumab is antiangiogenic monoclonal antibody against vascular 
endothelial growth factor (VEGF). They work by inhibiting the VEGF or EGF 
signaling and hence suppress the tumor’s ability to generate new blood 
vessels27,28. In terms of cancer chemotherapy, there are several physicochemical 
factors such as the molecular weight, stability, and hydrophobicity of drugs as well 
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as pathophysiological and  anatomical factors such as their inefficient 
accumulation in tumor tissues, the involvement of various chemo-resistance 
mechanisms by cancer cells among others, that contribute to the inefficient 
therapeutic outcomes of the HCC systemic chemotherapy28–31. 
1.3 Cancer Cells Chemoresistance 
Cancer cells are found to have tremendous ability to develop various 
resistance mechanisms to chemotherapeutic agents and to upregulate specific 
molecular targets and proteins that have essential roles in increasing tumor 
growth, invasiveness, and metastasis32,33.  
Chemoresistance mechanisms are various and principally include: 
Overexpression of P-glycoprotein (Pgp) and multidrug resistance associated 
proteins (MRP) that form efflux pumps which export the chemotherapeutic agents 
out of the cancer cells and help cells evade their cytotoxic effect34,35. The 
overexpression of growth factors and amplification of survival signals in response 
to chemotherapy induced stress, induction of enzymes metabolizing anticancer 
drugs, alteration of the drug target proteins so they have less binding affinity to the 
drug or alterations in the downstream signaling proteins, and downregulation of 
the drugs cellular transporters which decrease their effective concentration in 
cancer cells33,36.  
As a result, cancer cells no longer respond to chemotherapy, which 
consequently leads to treatment failure. Use of anticancer drugs which have 
different mechanisms of action in combination, or the use of drugs and 
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genes/siRNA combination could be an alternative approach to overcome tumor 
cells resistance and restore their therapeutic responsiveness36,37. 
1.4 Nrf2 (nuclear factor erythroid 2-related factor 2) Transcription Factor 
Nrf2 is a key transcription factor that has a fundamental role in the cellular 
defense against different toxicants, xenobiotics and any internal or external 
oxidative insults. 
1.4.1 Nrf2 Mechanism of Action 
Nrf2 works in the Nrf2- Keap1 (Kelch-like erythroid cell-derived protein1) - 
ARE (antioxidant response element) signaling pathway. Under normal conditions, 
the transcription factor Nrf2 binds to its repressor protein Keap1 which marks it for 
ubiquitination and subsequent proteasomal degradation38,39. However when cells 
are exposed to oxidative stress, the Keap1 protein gets covalently and 
conformationally modified in a way that no longer promotes Nrf2 ubiquitination and 
degradation with subsequent Nrf2 stabilization and accumulation in the 
cytoplasm40,41.  The accumulated free Nrf2 in the cytoplasm then translocates to 
the nucleus where it dimerizes with Maf (masculoaponeurotic fibrosarcoma) 
protein and binds to the AREs in regulatory region of many metabolic, antioxidant 
and cytoprotective genes to induce their transcription42. Among the genes which 
Nrf2 promotes their transcription are the genes of : GSH (glutathione) forming and 
metabolizing enzymes, antioxidant proteins, reactive oxygen species neutralizing 
enzymes, drug metabolizing enzymes, efflux pump multidrug resistance protein 1 
(MRP1)43. All these proteins are known to participate in the cellular protection and 
detoxification processes. 
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1.4.2 Dual Role of Nrf2 in Cancer 
There is dual role noted for Nrf2 and it may be considered as a double-
edged sword. While on one hand Nrf2 helps to protect the normal cells from 
neoplastic transformation (when exposed to various carcinogens), by reducing the 
reactive oxygen species (ROS) burden and by acting against DNA damage in cells, 
on the other hand, it promotes the cancer cells survival and increases their chemo 
and radio resistance. As a consequence, high levels of Nrf2 in cancer patients 
were reported to be an indicator of poor prognosis44,45.  
Nrf2 was found to be constitutively elevated and activated in many cancer 
types including: breast46,47, hepatocellular48,49, prostate50, gall bladder51, 
oesophageal52, pancreatic53 and non-small-cell lung54 carcinomas. As illustrated 
in figure 1.1, Nrf2 promotes cancer cells proliferation and chemoresistance. In 
various carcinomas, elevated Nrf2 level promotes cells aggressive proliferation 
and anabolism through induction of purine nucleotides (DNA and RNA forming 
units) synthesizing enzymes, glutathione (mitosis and cell cycle promotor) 
synthesizing enzymes55 as well as glucose metabolizing enzymes expression56. 
Highly activated Nrf2 contributed to resistance development to many 
chemotherapeutic agents such as doxorubicin, cisplatin, and 5-fluorouracil (5-FU). 
Nrf2 mediated chemoresistance mechanisms reported include induction of 
expression of genes encoding antioxidant proteins, as well as drug detoxifying 
enzymes and increasing drug efflux pumps production44,45.  
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Figure 1.1. Schematic illustration of Nrf2 roles in enhancing cancer cell proliferation and development of chemoresistance to anticancer chemotherapeutic drugs. 
1.4.3 Nrf2 in Hepatocellular Carcinoma 
In addition, Nrf2 was reported to have a  proven role in cancer proliferation, 
invasion and metastasis in HCC through regulation of Bcl-xL (antiapoptotic protein) 
and MMP-9 (matrix metalloproteinases-9, a protein regulating cell migration and 
invasion) expression49. Literature suggested that Nrf2 is involved in 
chemoresistance in HCC and its inhibition by sorafenib can sensitize cancer cells 
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to 5-FU57.  It was also reported that Nrf2 down regulation by miRNA-340 reversed 
cisplatin resistance in Hep G2 /cisplatin resistant HCC cells58. In another study, it 
was documented that apigenin resensitized HCC BEL-7402/doxorubicin resistant 
cells to doxorubicin via reducing Nrf2 expression59. These results emphasize the 
importance of targeting Nrf2 in fighting HCC. In this study we applied RNA 
interference (RNAi) technique, using polymeric micelles loaded with Nrf2 siRNAs 
to knockdown Nrf2 gene in Hep G2 hepatocellular carcinoma cell line in which Nrf2 
was reported to be mainly distributed in the cytoplasm60. 
1.5 Small Interfering RNA (siRNA) Therapy 
RNA interference (RNAi) is an efficient post-transcriptional gene silencing 
process. RNAi through small interfering RNA (siRNA) is highly regarded as a 
promising therapeutic strategy to inhibit and silence specific genes involved in 
pathogenesis of different diseases61–64.  
1.5.1 Mechanism of Action 
siRNA is small double stranded RNA (21-23 nucleotides) that are able to 
target a specific mRNA of complementary sequence. In the cytoplasm, siRNA is 
loaded in RNA-induced silencing complex (RISC), where its sense strand 
(passenger strand) gets cleaved by the argonaute 2 (AGO 2) protein. The activated 
RISC carrying the antisense strand (guide strand) recognizes the complementary 
sequence in the target mRNA and mediates its degradation with consequent 
mRNA specific gene silencing65–68. 
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1.5.2 Systemic Delivery Barriers 
Researchers faced multiple challenges during the systemic delivery of 
naked siRNAs, which end up with insufficient accumulation in cytosol of target cells 
and hence result in poor therapeutic outcomes. These obstacles include: 
degradation in serum with the endonucleases after intravenous injection, short 
plasma half-life (< 10 minutes) and rapid renal clearance69, also its very large size 
and high negative charge prevents it from diffusion through the anionic cell 
membrane readily61,70. As a result, therapeutic application and significant clinical 
benefit of siRNA are dictated by the availability of safe, well designed, effective 
siRNA carriers or delivery systems70,71.  
In this regard, several different nanocarriers have been used and studied 
for protecting and delivering siRNA efficiently to the cytoplasm of target cells. 
Among these, nanotechnology utility has helped to improve the biological stability 
of siRNAs, their pharmacokinetics as well as cellular uptake. Thus far, using such 
systems, satisfactory therapeutic outcomes have been obtained72,73.    
1.6 Nanocarriers, Drugs/Genes Delivery Systems, As Solution to Chemotherapy Problems 
It is a well-known fact that delivery of siRNAs and drugs to the target organs 
and tissues has been a challenge. In terms of delivery strategies, many 
nanocarriers including dendrimers, liposomes, polymeric nanoparticles and 
polymeric micelles have been extensively studied to achieve either passive or 
active targeting of chemotherapeutic agents or siRNA/genes to the tumor 
tissues74,75.  
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These nanosystems not only accumulate in the cancerous tissue by 
exploiting the leaky tumor vasculature or the enhanced permeability and retention 
(EPR) effect but can also be internalized into the tumor cells by receptor mediated 
uptake76,77. Nanocarriers also protect the drugs/nucleic acids from burst release or 
degradation, improve their cargo pharmacokinetics, increase drug solubility, and 
reduce toxicity as well as unfavorable side effects thereby enhancing patient 
compliance74,75,78.  Although several nanocarriers are under development or in the 
clinical trials stages, only a few have been approved by the FDA. These 
shortcomings necessitate the need to fast-track the development of delivery 
technologies, including the more promising and beneficial targeted nanodelivery 
systems1,79.   
1.6.1 Polymeric Micelles 
Polymeric nanomicelles are one class of nanocarriers that are constructed 
from amphiphilic block copolymers that can self-assemble in aqueous environment 
to form spherical core-shell structures, at concentration above the critical micellar 
concentration (CMC)80,81. Amphiphilic copolymers are composed of hydrophilic 
and hydrophobic moieties and when CMC is reached the hydrophobic moieties  
start to come closer to each other and away from water to reach more favorable 
entropy forming the micellar core while the hydrophilic moieties form the micellar 
shell82. Different hydrophobic drugs have been loaded in micellar core through their 
interaction with the core hydrophobic groups. On the other hand, hydrophilic shell 
groups confer water solubility and diminish protein (opsonin) adsorption on 
micelles, which consequently improves the micelle’s cargo blood stability and 
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circulation half-life83. It is proven that solubility, stability and circulation time of 
hydrophobic chemotherapeutic agents are enhanced by their encapsulation in the 
micellar core78,82,84. Being water soluble and of nanosize, micelles carrying 
hydrophobic anticancer drugs can be administered intravenously to achieve better 
drug penetration and passive accumulation in the tumors83,85.  Functionalization of 
the micellar shell with targeting ligands not only allow their active accumulation 
selectively in tumor tissues, but also decrease the chemoresistance to their drug 
cargo through evasion of efflux pumps and achieving receptor mediated 
endocytosis75,86. Different types of polymeric nanomicelles are illustrated in figure 
1.2. 
1.6.2 Multifunctional Polymeric Micelles for Cancer Therapy 
Multifunctional polymeric micelles as the name suggests, are the ones in 
which more than one therapeutic agent, or therapeutic and diagnostic/imaging 
agents can be integrated on the same micellar carrier, with or without the 
attachment of targeting moieties for selective delivery80. It is well documented that 
multifunctional micellar nanocarriers can help achieve synergistic control over 
cancer growth by co-delivery of genes/ siRNA and chemotherapeutics at the same 
time87–89. Co-delivery of different therapeutic agents that work by different 
mechanisms of action is a desirable approach to overcome cancer 
chemoresistance and improve therapeutic efficacy90. Theranostic multifunctional 
polymeric micelles have been reported to perform both therapeutic and imaging 
functions through incorporation of imaging probes as well as therapeutic 
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drugs/genes in the micellar constructs91,92. Multifunctional micelles as a result, has 
a great potential for application in cancer therapy. 
 
Figure 1.2. Schematic illustration of different types of polymeric nanomicelles.  1.7 Poly(styrene-co-maleic anhydride partial iso-octyl ester) (SMAPIE) Copolymer, As a Micellar Core Building Block 
In terms of the nanomicellar carrier building polymers, poly(styrene-co-
maleic anhydride partial iso-octyl ester) (SMAPIE) is a partial ester of the well-
studied polystyrene-co-maleic anhydride (SMA) copolymer. It is established that 
the hydrophobic styrene groups in SMAPIE copolymer can participate in formation 
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of compact micellar core during fabrication of polymeric micellar delivery systems 
for efficient encapsulation and delivery of hydrophobic anticancer drugs93,94. In 
terms of the use of SMA for drug delivery applications, the base polymer has been 
proven to be safe for in vivo use. Indeed SMA polymer was used in the synthesis 
of many polymeric drug conjugates such as fenoprofen-SMA and gemfibrozil-SMA 
conjugates95, SMA-neocarzinostatin (also known as SMANCS)96 and SMA 
conjugated YIGSR97. The micellar SMA-doxorubicin98 and SMA-pirarubicin 99 also  
showed better pharmacokinetic and pharmacodynamic profiles compared to those 
of the free drug in animal tumor models.  
1.8 Branched Polyethylenimine (PEI) Polymer, As a Micellar Shell Building Block 
Polyethylenimine (PEI) polymer has many hydrophilic amine groups that 
can be used to form hydrophilic shell of a micellar system. In addition, PEI  is one 
of the most efficient cationic polymers used for gene/siRNA delivery both in vitro 
and in vivo applications100–102.  As a cationic polymer it is relatively  safer, less 
immunogenic,  simpler to prepare and cheaper than the viral vectors103. PEI 
cationic amine groups can efficiently condense anionic phosphate groups of 
nucleic acids via electrostatic interaction and improve their cellular uptake via 
endocytosis104. The intrinsic endosomolytic ability of PEI allows the endosomal 
escape of the delivery system cargo via the “proton sponge” mechanism and 
hence can increase transfection efficiency105. The “proton sponge” effect of the 
protonatable amine groups causes the protons and water influx in the endosomes, 
which results in the endosomal membrane rupture releasing the drugs/siRNA 
cargo into the cytoplasm after evasion of the lysosomal degradation71. In addition, 
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modification of some of the amine groups of PEI with targeting moieties can reduce 
its charge density, cytotoxicity and improve its targeting ability104,106. Modification 
of PEI with targeting ligands or imaging agents can be efficiently done using copper 
free “click” chemistry. 
1.9 Copper Free “Click” Chemistry Application in Micellar Surface Functionalization 
Copper free “click” chemistry is a simple, rapid, highly selective, water 
compatible, and bioorthogonal chemical approach that involves ligation of two 
moieties through strain promoted 1, 3 dipolar azide alkyne cycloaddition107,108. 
Copper free “click” synthetic module is more useful compared to the copper 
catalyzed “click”  reactions since copper free reactions don’t involve the oxidative 
damage and toxicity that could be caused to the cells and tissues due to residual 
copper catalyst remaining in the purified product109. As shown in figure 1.3, the 
driving force for the copper free “click”  approach is the strain of alkyne 
encountering ring, as in the dibenzyl cyclooctyne (DBCO) ring instead of the 
copper catalyst in the copper catalyzed reaction108. The copper free “click” type 
reported by Bertozzi and co-workers is biocompatible and bioorthogonal reaction 
that can occur inside the living systems without inducing toxicity or interfering with 
native biological molecules or processes107.  
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Figure 1.3. Schematic illustration of the strain-promoted alkyne-azide cycloaddition copper free “click” reaction (SPAAC) and the copper-catalyzed alkyne-azide cycloaddition “click” reaction (CuAAC). 
“Click” chemistry has been used in many applications including biorthogonal 
imaging or labeling of different biomolecules as proteins or nucleic acids using 
alkynyl or azido sugars or amino acids probes110–114, in situ fragment based drug 
development with example of multivalent enzyme or receptor inhibitors 
construction115,116, synthesis of fluorescently labeled targeted drug nanocarriers 
for cancer therapy and imaging117. 
In this study we synthesized azide modified modular micellar platform that 
can be decorated off-the-shelf with different cyclooctyne linked targeting moieties 
or imaging agents simultaneously using the same rapid copper free “click” reaction 
to arrive at nanomicelles suitable for theranostic and metastatic cancer therapy 
application. Importantly, the concept can be utilized to quickly assemble the 
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micellar nanocarriers constructed using off-the-shelf library of the synthesized 
azide/alkyne block co-polymers (containing various drug and gene payloads) 
decorated with various targeting ligands for treating multiple different cancers that 
overexpress several kinds of receptor domains. 
1.10 Galactosamine as Efficient Targeting Ligand for Selective HCC Therapy 
Galactosamine is among the selective targeting ligands used for targeting 
hepatocellular carcinoma due to its high binding affinity to asialoglycoprotein 
receptor. Asialoglycoprotein receptors (ASGPRs), also known as (Ashwell 
receptor) are lectin receptors that were found to be over expressed in several 
human neoplastic hepatocytes118 and   HCC cell lines including Hep G2 and 
Huh7.5 cells119,120. ASGPRs selectively binds and internalize different molecules 
exposing carbohydrate residues as galactose, galactosamine, or N- 
acetylgalactosamine through clathrin type receptor mediated endocytosis121,122.  
Galactosamine was proven to achieve ASGPR mediated efficient liver 
tumor targeting in phase I clinical trial of poly[N-(2-hydroxypropyl)methacrylamide] 
copolymer carrying doxorubicin and galactosamine, as reported by Peter J. Julyan 
and co workers123.  In the same line, Zheyu Shen, et al. showed increased cellular 
uptake and cytotoxicity of galactosamine targeted doxorubicin loaded albumin 
nanoparticles compared to non-targeted counterparts124. Similarly, Yu Cai Wang 
et al. demonstrated that galactosamine conjugated micelles loaded with paclitaxel 
exhibited better drug internalization, cytotoxicity and induction of cell cycle arrest 
in contrast to the paclitaxel loaded micelles without galactosamine ligand125. As a 
result, galactosamine is a well-studied effective targeting moiety for hepatoma cells 
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expressing ASGPR. Galactosamine conjugated delivery systems could thus be 
very promising in achieving more effective HCC therapy, with better accumulation 
of therapeutic agents in the tumor tissue and lesser side effects.  
In the present work, we engineered polymeric nanomicelles which can be 
multifunctional in use and can be utilized as modular platform for delivering 
chemotherapeutic drugs, imaging agents, and genes/siRNA simultaneously or 
individually, in a targeted manner to one or more cancer type. Our amphiphilic 
micellar copolymer is composed of SMAPIE copolymer grafted to hyperbranched 
PEI polymer, with the hydrophobic styrene groups forming the compact micellar 
core and the hydrophilic polyethylenimine amino branches forming the coronal 
layer. The role of PEI is for efficient complexation of siRNAs and genes. We 
partially converted primary amine groups in PEI polymer to azide groups, so that 
copper free “click” chemistry could be employed to conjugate targeting ligands or 
imaging moieties to decorate the nanomicelles. As a proof-of-concept in this study 
we synthesized galactosamine targeted nanomicelles for selective delivery of Nrf2 
siRNA in HCC cells. As illustrated in figure 1.4, the targeted micelles were able to 
achieve selective high cellular uptake via ASGPR mediated endocytosis and 
statistically significant Nrf2 gene knockdown in the tested HCC. 
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Figure 1.4. Schematic illustration of galactosamine conjugation to the modular polymeric SMAPIE-PEI-N3 micelles, the SMAPIE-PEI-Gal micelleplexes formation followed by their uptake in HCC cells via receptor mediated endocytosis to achieve siRNA mediated Nrf2 gene knockdown.
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CHAPTER 2 EXPERIMENTAL DESIGN 
2.1 Materials  
Branched polyethylenimine (PEI) with average molecular weight 10 KDa 
was purchased from polysciences (Warrington, PA). Branched polyethylenimine 
(PEI) with average molecular weight 25 KDa, Poly(styrene-co-maleic anhydride, 
partial iso-octyl ester) cumene terminated (SMAPIE) with average molecular 
weight 2.3 KDa, β-D(+)-Glucose, Glycine, Ammonium persulfate, Glycerol, 
Sodium dodecyl sulfate, 2- Mercaptoethanol, N,N,N′,N′-
Tetramethylethylenediamine, MISSION siRNA Universal Negative Control #2 
(SIC002), and RNAase free water,  were purchased from Sigma-Aldrich (St Louis, 
MO, USA). D-(+)-Galactosamine.HCl was obtained from MP BioMedicals, LLC 
(Solon, OH, USA). Dibenzyl cyclooctyne – (polyethylene glycol) 5 –N-hydroxy 
succinimide (DBCO-PEG5-NHS) ester was purchased from Click Chemistry Tools 
Bioconjugate Technology Company (Scottsdale, AZ, USA). Potassium carbonate 
was purchased from Fisher science education (Nazareth, PA, USA). Pyrene was 
from Acros (NJ, USA). SYBER Gold nucleic acid gel stain was obtained from 
Invitrogen life technologies (Carlsbad, CA, USA).  Dulbecco’s modified eagle 
medium (DMEM), FluoroBrite TM DMEM life cell fluorescence imaging medium, 
Phosphate-buffered saline (PBS), fetal bovine serum (FBS), penicillin-
streptomycin (Pen-Strep), and Trypsin-EDTA (0.25%) with phenol red solution 
were from Gibco, Thermo Fisher Scientific (Waltham, MA, USA). Tris base 
(hydroxyl Methyl amino Methane), Pierce protease and phosphatase inhibitor mini 
tablets, and Super Signal West Pico chemiluminescent substrate were obtained 
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from Thermo Fisher Scientific (Waltham, MA, USA). Goat anti-mouse IgG-HRP sc-
2005 secondary antibody, Nrf2 (A-10) sc-365949 mouse monoclonal primary 
antibody, GAPDH (G-9) sc-365062 mouse monoclonal primary antibody, and Nrf2 
siRNA (h) sc-37030 were purchased from Santa Cruz Biotechnology, Inc. (Dallas, 
TX, USA). MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide) 
was obtained from Gold Biotechnology (St Louis, MO, USA). Silencer® FAM™-
Labeled Negative Control #1 siRNA was obtained from Applied Biosystems 
Ambion, Inc. (Austin, TX, USA). Lyso Tracker Deep Red fluorescent dye, and 
Hoechst 33342, Trihydrochloride Trihydrate nucleic acid stain were purchased 
from Life Technologies (Carlsbad, CA, USA). Bradford protein assay dye reagent 
concentrate, 10% Tween 20 solution, and 30% Acrylamide/Bis solution were 
bought from BIO-RAD (Hercules, CA, USA). Imidazole-1-sulfonylazide 
hydrochloride reagent was synthesized in our lab according to previously reported 
method126. All other reagents and Solvents were of analytical grade and were used 
without further purification. 
2.2 Cell Culture  
The human HCC cell line (Hep G2) was a kind gift from Dr. John J. Reiners 
(Wayne State University, Detroit, MI, USA). Cells were cultured in DMEM medium 
supplemented with 10% fetal bovine serum (FBS), 4 mM L-Glutamine, (4.5 g/L D-
glucose), (3.7 g/L sodium bicarbonate) and 1% penicillin-streptomycin solution at 
37 ̊C in humidified air containing 5% CO2. Cells were maintained and sub-cultured 
every 3 to 4 days at approximately 80% confluency. 
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2.3 Synthesis and Characterization of SMAPIE-PEI-N3 and SMAPIE-PEI-Gal Micelles  2.3.1 Synthesis of SMAPIE-PEI-N3 Micelles Forming Block Copolymer 
SMAPIE-PEI-N3 micelles were synthesized in two steps by one pot reaction 
method. First, previously reported method127 was followed, with some 
modifications. Briefly, PEI 10 KDa (250 mg, 0.025 mmole) was dissolved in 47 mL 
methanol followed by addition of 23 mL DMSO to it. SMAPIE 2.3 KDa (57.5 mg, 
0.025 mmole) was dissolved in 23 mL DMSO followed by addition of 47 mL 
methanol. Subsequently, SMAPIE solution was added in a dropwise fashion onto 
the PEI 10 KDa solution with continuous stirring using a magnetic stirrer. The 
dropping rate was fixed at about 12 drops/min. The reaction mixture was then kept 
under continuous stirring at room temperature overnight.  
In the next step, conversion of some of the primary amine groups in PEI to 
azide groups was undertaken using a previously published method126, with some 
modifications. In brief, potassium carbonate (216.4 mg, 1.566 mmole) was added 
to the crude reaction mixture from the previous step while stirring on ice, followed 
by the portion wise addition of imidazole-1-sulfonylazide hydrochloride reagent 
(109.4 mg, 0.522 mmole). The ice bath was removed and the reaction was kept 
under stirring at room temperature for 24 hours. The reaction mixture was then 
dialyzed using dialysis bag (MWCO 10KDa, Spectra/Por, Spectrum Labs, San 
Diego, CA, USA) against deionized water for 2 days with frequent changes of the 
dialysis water to remove solvents, salts and any small molecular weight unreacted 
reagents. Then, the dialysis was continued against deionized water for another 6 
hours using a dialysis bag (MWCO 12-14 KDa, Spectra/Por, Spectrum Labs, San 
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Diego, CA, USA) to get rid of unreacted PEI. The final dialyzed product was filtered 
using Whatman filter paper to remove any precipitate or crosslinked product. The 
dry SMAPIE-PEI-N3 product was obtained by lyophilization (yield 86%).  
The successful synthesis of SMAPIE-PEI-N3 product was confirmed by 
Fourier transform infrared spectroscopy (JASCO, FT/IR - 4200 Fourier Transform 
Infrared Spectrometer, Japan) and Proton nuclear magnetic resonance (1H NMR) 
spectroscopy (600 MHz, Agilent-NMR-inova600, Santa Clara, CA, USA). 
FT-IR (ν, cm-1): 2500-3700 (carboxylic acid broad –OH stretch), 2105 (azide 
–N3 stretch), 1749 (ester –C=O stretch), 1700 (little shoulder of carboxylic acid –
C=O stretch), 1671 (secondary amide –C=O stretch), 1519 (aromatic benzene ring 
C=C stretch). 
1H NMR (d4-CD3OD): δ (ppm) = 0.86 (overlapping peaks of: -CH3 in cumene 
terminal and –CH(CH3)2 in iso-octyl chain), 1.15-1.8 (overlapping peaks of: –
CH(CH3)2,  -CH2 - in iso-octyl chain and -CH2CHPh), 2.2-3 (-CH2CH2NH- in PEI), 
3.1-3.6 (overlapping peaks of: -COCH-, -OCH2-, -CH2NHCO- and -NHCH2CH2N3 
in PEI chain), 6.4-7.4 (C6H5- in cumene terminal and styrene residues). 
2.3.2 Synthesis of Targeting Ligand Conjugated SMAPIE-PEI-Gal Micelles Forming Block Copolymer 
Galactosamine targeted micelles, SMAPIE-PEI-Gal, were synthesized by 
copper free “click” chemistry according to a protocol provided by Click Chemistry 
Tools company (Scottsdale, AZ, USA) in two steps, with some modifications. First, 
the galactosamine.HCl (20.2 mg, 0.0936 mmole) was dissolved in 3mL 1X 
phosphate buffer saline (PBS). Then, triethylamine (Et3N) (13 µl, 0.0936 mmole) 
was added to the solution to obtain the galactosamine in its basic form so that it 
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can efficiently react with the NHS ester. DBCO-PEG5-NHS ester (21.65 mg, 
0.0312 mmole) was dissolved in 400 µl DMSO and then added to the solution 
containing galactosamine to obtain the product, galactosamino-PEG5-DBCO. The 
reaction mixture was kept under stirring at room temperature for 6 hours in order 
to allow the reaction to proceed to completion.  
In the next step, galactosamino-PEG5-DBCO obtained in the first step was 
reacted with SMAPIE-PEI-N3 micelles as follows: SMAPIE-PEI-N3 (50 mg) was 
dissolved in 7 mL deionized water and added to the solution containing 
galactosamino-PEG5-DBCO obtained from step one. The reaction mixture was 
stirred at room temperature for 12 hours. The product was dialyzed using  a dialysis 
bag (MWCO 10KDa, Spectra/Por, Spectrum Labs, San Diego, CA, USA) against 
deionized water for 1 day with frequent changes to the dialysis water to remove 
solvents, salts and any small molecular weight unreacted reagents. The dried final 
product, SMAPIE-PEI-Gal was obtained by lyophilization (yield 99%).  
The successful synthesis of SMAPIE-PEI-Gal targeted micelles forming 
block copolymer was confirmed by proton nuclear magnetic resonance (1H NMR) 
spectra recorded on 600 MHz spectrometer (Agilent-NMR-inova600, Santa Clara, 
CA, USA). 
1H NMR (d2-D2O): δ (ppm) = 1.4 (overlapping peaks of: -CH3 in cumene 
terminal and -CH(CH3)2 in iso-octyl chain), 1.7 (overlapping peaks of: -CH2 - in iso-
octyl chain and -CH2CHPh), 2.2-3 (-CH2CH2NH- in PEI), 3-3.49 (overlapping peaks 
of: -COCH-, -OCH2- in SMAPIE, -CHNH2 protons in galactosamine alpha and beta 
anomers and -OCH2CH2O- in PEG chain), 3.5-4 (-CH2CHCHOH, -NH2CHCHOH, 
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-CH2OH, -CHCH2- protons in galactosamine alpha and beta anomers), 4.5, 5 (-
OCHOH alpha and beta anomeric protons in galactosamine), 6.4-7.6 (overlapping 
peaks of: -C6H4 in substituted DBCO and -C6H5 in cumene terminal and styrene 
residues). 
2.4 Size Exclusion Chromatography (SEC) 
Gel filtration chromatography (GFC), a type of size exclusion 
chromatography, was performed to determine the molecular weight of SMAPIE-
PEI-N3 micelles relative to molecular weight of protein standards. Briefly, the 
samples were prepared in 0.45 µm filtered deionized water (6 mg/mL) and 
sonicated using Branson 8210 ultrasonifier for 20 min. The sample was then 
injected in Hiload 16/600 Superdex 75 pg column in AKTA FPLC system (GE 
Healthcare Lifesciences, Pittsburgh, PA, USA). The sample was run at a flow rate 
0.3 mL/min using (300 mM NaCl, 50 mM Na2HPO4/NaH2PO4, 10% acetonitrile) as 
running buffer (pH 7.2) at 4˚C. UV detector was set at 280 nm for detection of 
aromatic benzene ring in SMAPIE chain. Elution volume was used to calculate the 
relative molecular weight using standard curve of log molecular weights of protein 
standards versus standards Ve/Vo (elution volume/ column void volume). 
2.5 Copper Assay  
A copper based assay was performed to quantify the amount of PEI in 
SMAPIE-PEI-N3 and SMAPIE-PEI-Gal micelles according to previously described 
method128. Briefly, using a 96 well plate, 50 µL of 20 mM copper acetate in 5% Na 
acetate solution was added to 50 µL of either SMAPIE-PEI-N3 or SMAPIE-PEI-
Gal solution (2 mg/mL) in deionized water. The intensity of the blue colored 
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cuprammonium complex was measured at 690nm on a synergy 2 microplate 
reader (BioTek Instrument, Winooski, VT, USA).  
The concentration of PEI in targeted and non-targeted micelles was 
calculated based on the calibration curve constructed using PEI 10 KDa as 
standard at varied concentrations (2, 1, 0.5, 0.25, 0.125, 0.0625 mg/ml). Results 
were presented as mean (± SD), n=3 and n=4 in case of PEI 10 KDa standard and 
micelles respectively.  
2.6 Determination of Critical Micelle Concentration (CMC) 
CMC was determined by fluorescence spectroscopy using pyrene as a 
fluorescent probe4. Briefly, 100 µl of pyrene solution in methanol (12 µM) was 
added into amber colored bottles and left in chemical hood overnight to allow 
methanol evaporation and pyrene film formation. Then varying copolymer 
concentrations in water (0.0001-0.5 gm/L) was prepared in triplicates and added 
to the pyrene film to get pyrene final concentration of (0.6 µM). The solutions were 
kept on a shaker at room temperature for 24 hours. Subsequently, the 
fluorescence measurement was performed on F-2500 fluorescence 
spectrophotometer (Hitachi,Ltd. Tokyo, Japan). The measurements were done at 
excitation wavelengths of 334 nm and 339 nm and emission wavelength of 390 
nm. The emission intensity ratio (I339/I334) was plotted against the logarithm of 
the copolymer concentrations. The CMC value was obtained from the intersection 
of the tangential lines on the curve as reported previously130. Results were reported 
as mean (± SD, n=3). 
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2.7 Preparation of siRNA Micelleplexes or Polyplexes 
Micelleplexes or polyplexes were prepared according to the pre-calculated 
N/P ratio, which is the ratio of positively charged amine groups (N) in the polymer 
to the negatively charged phosphate groups (P) in siRNA. Both micelles/polymer 
and siRNA solutions were prepared in sterile filtered 5% glucose solution using 
0.22 µm syringe filter. Equal volumes of siRNA solution and micelles/polymer 
solution were efficiently mixed and pipetted many times, then incubated at room 
temperature for 30 min to allow efficient complexation. Micelles/polymer solutions 
of different concentrations were used to form micelleplexes or polyplexes at the 
desired various N/P ratios. 
2.8 SYBER Gold Assay 
SYBER Gold quenching assay was performed to evaluate the siRNA 
condensation capacity of both targeted (SMAPIE-PEI-Gal) and non-targeted 
(SMAPIE-PEI-N3) micelles at different N/P ratios (1, 2, 3, 4, 5, 10, 15) in 
comparison to PEI 25 KDa and PEI 10 KDa as controls. SYBER Gold assay was 
conducted according to previously reported procedure131 with some modifications. 
For this purpose, white/opaque FluoroNunc 96 well plate was used. In each well, 
50 pmol of siRNA Universal Negative Control #2 in 50 µL of sterile 5% glucose 
solution was complexed with 50 µL of micelles or polymer solution prepared at the 
suitable concentration in sterile 5% glucose solution to achieve the desired N/P 
ratio. The (100 µL) in each well was incubated for 30 minutes at room temperature. 
Then, 30 µL of 4x SYBER Gold solution was added to each well and the plate was 
incubated in the dark at room temperature. After 15 minute incubation, 
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fluorescence was detected using a synergy 2 microplate reader (BioTek 
Instrument, Winooski, VT, USA) at excitation and emission wavelength of 
485/20nm and 528/20nm respectively. Results were represented as mean (± 
standard deviation, n=3). Fluorescence intensity at N/P = zero (free siRNA + 
SYBER Gold dye) was set as 100% and relative fluorescence intensities of 
micelleplexes or polyplexes was obtained using the equation: [(micelleplexes or 
polyplexes fluorescence intensity) / (fluorescence intensity at N/P= zero)]* 100. 
2.9 Size and Zeta Potential Measurements: Light Scattering (LS) 
Hydrodynamic size and zeta potential measurements of siRNA free 
micelles, siRNA containing micelles (micelleplexes) and PEI 10 KDa polyplexes 
were performed in triplicates using light scattering (LS) analysis.  All samples were 
tested in a Zetasizer Nano ZS (Malvern Instruments, Westborough, MA, USA) at 
25 ̊C. The siRNA free micelles samples were prepared in deionized water (1mg/ml) 
and tested at a volume of 350 µl and 750 µl using disposable cuvettes for size and 
zeta potential determination respectively. Micelleplexes or PEI polyplexes sizes 
were measured by transferring 100 µl of micelleplexes or PEI polyplexes solution 
in sterile filtered 5% glucose to low volume disposable cuvette, where each 100 µl 
contained 20 pmol of siRNA. After size measurement, the same sample (in 100 µl 
volume) was diluted with 650 µl sterile filtered 5% glucose solution and transferred 
into transparent zeta cuvette for zeta potential measurements using the same 
instrument. The scattered light was detected at 173˚ backscatter angle, distilled 
water viscosity and refractive index of (0.8872 cP) and (1.33) respectively, were 
used as measuring parameters. Samples in triplicates where tested and three 
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measurements were performed for each sample with at least 12 runs per 
measurement. Size and zeta measurements Results were presented as Z-average 
hydrodynamic size in nanometers (± SD, n=3) and mean in millivolts (± SD, n=3), 
respectively. 
2.10 Size and Morphology Measurements: Transmission Electron Microscopy (TEM) 
The size and morphology of siRNA free micelles and micelleplexes in the 
dry state were obtained by transmission electron microscopy TEM. TEM samples 
were prepared by adding a drop of siRNA free micelles solution (4mg/ml), or 
micelleplexes solution (prepared as described above at N/P ratio of 10 with 40 
pmol siRNA Universal Negative Control #2 in total volume of 10 µl) on a copper-
coated grid (200 mesh) for 3 minutes followed by blotting the grid, and staining 
with 3% uranyl acetate for another 3 minutes. Finally, the grid was allowed to air 
dry completely before imaging. Sterile filtered 5% glucose solution was used as 
the dispersion medium for sample preparation. Several images at different 
magnifications were obtained for each sample with a transmission electron 
microscope (JEOL 2010 TEM, LaB6 Filament Gun, Tokyo, Japan). 
2.11 Buffering Capacity Measurements  
An acid-base titration was performed to determine the buffering capacity of 
both targeted SMAPIE-PEI-Gal and non-targeted SMAPIE-PEI-N3 micelles in 
comparison to PEI branched polymers of different molecular weights (25, 10, 1.8 
KDa) as positive controls and 150 mM NaCl solution as vehicle and negative 
control. The assay was done according to previously reported procedure132. 
Briefly, 3 mg polymer or micelles were dissolved in 15 ml of 150 mM NaCl solution 
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to achieve final concentration of 0.2 mg/mL. The pH of all solutions was adjusted 
at the beginning to 11.0 by titration against 0.1 M NaOH solution. Subsequently, 
titration curve was generated for each polymer or micelle by titrating their solutions 
with 0.1 M HCl solution at equal increments of 30 µL till pH of 2.0. The changes in 
pH values were determined after each 30 µL addition using a pH meter at room 
temperature. The slower the change in the pH of the solution during titration the 
higher its buffering capacity and vice-versa.  
2.12 Biological Evaluation of SMAPIE-PEI-N3 and SMAPEI-PEI-Gal Micelles 
2.12.1 Cytotoxicity Assay Using Human Liver Cancer Cells  
The cytotoxicity of free polymers (PEI 25 KDa and PEI 10 KDa as controls) 
or micelles (non-targeted SMAPIE-PEI-N3 and targeted SMAPIE-PEI-Gal) was 
studied using MTT assay on Hep G2 human HCC cells. The Hep G2 cells were 
seeded in 96 well plates at cell density of 5000 cells/well in 100 µL of DMEM growth 
medium containing 10% FBS and incubated for 24 hours at 37  ̊C in humidified air 
containing 5% CO2. Stock solutions of different polymers or micelles were 
prepared in sterile 5% glucose solution. Predetermined concentrations were 
obtained by serial dilution of the respective stock solutions with cell culture medium 
supplemented with FBS.  Subsequently, 100 µL of each serial dilution was added 
on the preexisting 100 µL media in each well to achieve final polymer or micellar 
concentrations ranging from 400 to 1.5625 µg/mL. The cells were incubated for 48 
hours. MTT solution in phosphate buffered saline (PBS; 5 mg/mL) was then added 
to cells (20 µL/well), and the plates were incubated for additional 3 hours at 37 ̊C 
and 5% CO2. Then, all the media were removed and 100 µL of dimethyl sulfoxide 
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(DMSO) was added in each well and the plates were subjected to orbital shaking 
in the dark for 15 minutes. The DMSO solvent dissolved the purple colored 
formazan crystals formed in the mitochondria of live cells. The absorbance was 
recorded at 590 nm on a synergy 2 microplate reader (BioTek Instrument, 
Winooski, VT, USA). Results were presented as mean (± SD, n=3) of relative cell 
viability (%). Percentage relative cell viability = (treated cells absorbance – blank 
absorbance) / (untreated cells absorbance – blank absorbance) х 100. Treated and 
untreated cells are cells cultured in presence or absence of polymers or micelles, 
respectively. Blank values (controls) were attributed to the absorbance measured 
in wells that didn’t contain cells.  
2.12.2 Cellular Uptake Quantification by Flow Cytometry 
Flow cytometry was used to quantify the cellular uptake of the fluorescently 
labeled micelleplexes or polyplexes. Hep G2 cells were seeded in 24 well plates 
at cell density of 80,000 cells/well in 500 µL of DMEM containing 10% FBS and 
incubated for 24 hours at 37 ̊C and 5% CO2   prior to transfection. On transfection 
day, pre-existing medium was replaced with 350 µL fresh media containing 10% 
FBS. In case of competition assay, the 350 µL of fresh DMEM medium contained 
10% FBS and 20 mM free galactosamine as a competitor of galactsamine in 
SMAPIE-PEI-Gal micelles.  PEI 10 KDa polyplexes, targeted (SMAPIE-PEI-Gal) 
or non-targeted (SMAPIE-PEI-N3) micelleplexes were prepared as described 
above in 50 µL of sterile 5% glucose solution at N/P ratio of 10 using fluorescent 
FAM™-Labeled Negative Control siRNA. The prepared polyplexes or 
micelleplexes were added on cells to achieve final siRNA concentration of 200 nM 
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per well. Untreated cells (blank) or cells treated with free siRNA served as negative 
controls, while cells treated with PEI 10 KDa polyplexes served as positive control. 
After the polypexes or micelleplexes addition, cells were incubated at 37 ̊C and 5% 
CO2 for total transfection time of 5 hours. When the transfection period ended, the 
transfection medium was removed, and cells were washed with 1 mL sterile PBS. 
100 µL trypsin /well was added for 3 minutes to detach cells followed by addition 
of 900 µL fresh medium to deactivate the trypsin. Cell suspensions were collected 
and centrifuged at 4 ̊C for 5 minutes at 800 rpm, then supernatant was removed 
and cells were washed with 1mL sterile PBS by resuspension and re-
centrifugation. Finally, cells were re-suspended in 400 µL sterile PBS for 
fluorescence quantification using Attune® Acoustic Focusing Flow Cytometer 
(Applied Biosystems, Life Technologies, Carlsbad, CA,USA). The laser beam was 
set at a wavelength of 488 nm for excitation and (530/30) (center/band pass) 
emission filter was used for emission detection. Cells were gated based on their 
morphology and 10,000 events were evaluated per each sample. Measurements 
were performed in triplicates and data analysis was performed using Attune® 
Cytometric Software. Data are shown as mean of median fluorescence intensity (± 
standard deviation, n=3). Statistical analysis of data was completed through one-
way ANOVA and post hoc Tukey HSD test application using Vassar stats program.  
2.12.3 Cellular Uptake and Endosomal Escape by Confocal Laser Scanning Microscopy (CLSM) 
Cellular uptake of both targeted (SMAPIE-PEI-Gal) and non-targeted 
(SMAPIE-PEI-N3) micelleplexes through endocytosis and the ability to achieve 
endosomal escape with the release of the siRNA in cytoplasm was shown by 
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Confocal Laser Scanning Microscopy (CLSM, Leica microsystems, Mannheim, 
Germany). Hep G2 cells were seeded in 4 well µ-Slide Ph+, ibiTreat ( ibidi, 
Wisconsin, USA) at cell density of 35,000 cells/well in 600 µL of FluoroBrite TM 
DMEM life cell fluorescence imaging medium containing 10% FBS and incubated 
for 24 hours at 37 ̊C in humidified air containing 5% CO2  prior to transfection. On 
day of transfection pre-existing medium was replaced with 550 µL of fresh 
FluoroBrite TM DMEM medium containing 10% FBS. In case of competition assay, 
the 550 µL of fresh FluoroBrite TM DMEM medium contained 10% FBS and free 
galactosamine as a competitor of galactsamine in SMAPIE-PEI-Gal micelles. The 
free galactosamine was added to obtain final concentration of 100 µg/ml in total 
volume of 600 µL. Cells were transfected with micelleplexes or polyplexes at N/P 
ratio of 10. Polyplexes of PEI 10KDa as a positive control or micelleplexes of 
targeted (SMAPIE-PEI-Gal) or non-targeted (SMAPIE-PEI-N3) micelles were 
formed as described above using Silencer® FAM™-Labeled Negative Control 
siRNA in 50 µL of sterile 5% glucose solution, which was then added to the 550 
µL of fresh medium in each well to achieve final siRNA concentration of 200 nM. 
Then, cells were incubated for 20 hours at 37 ̊C and 5% CO2 before being washed 
with PBS PH 7.4. Subsequently, cells were incubated for 1 hour in 100 nM Lyso 
Tracker Deep Red dye solution in FluoroBrite TM DMEM medium containing 10% 
FBS to stain endosomes. Then, cells were washed with PBS PH 7.4. The nuclei 
were stained with 8.115 µM Hoechst 33342 stain solution in PBS following 
incubation of cells with the stain at 37 ̊C and 5% CO2 for 10 minutes. Finally, cells 
were washed with PBS and incubated in 700 µL FluoroBrite TM DMEM medium 
33  
  
containing 10% FBS. The cells were directly imaged by live cell imaging technique 
on Leica TCS SP5 inverted confocal microscope (Leica microsystems, Mannheim, 
Germany). All images were acquired using oil immersion lens with 63X 
magnification / 1.4 numerical aperture. For excitation of Hoechst 33342, FAM-
Labeled siRNA, and LysoTracker Deep Red Laser beams with excitation 
wavelengths 405nm, 488nm, and 633nm were used respectively. Merge images 
of the three fluorescent emissions as well as Bright field ones were recorded for 
each sample.  
Fiji ImageJ software (Life-Line version, 2015 December 22)133,134 was used 
for quantification of green siRNA fluorescence in the CLSM images. Fluorescence 
quantification was performed according to previously reported method135. Total 
corrected cellular fluorescence (TCCF) per cell was determined, where TCCF = 
integrated density obtained – (area of selected cell х fluorescence of background). 
After that, mean of TCCFs of all cells / image was calculated and plotted against 
each treatment type.    
2.12.4 Transfection Efficiency and Nrf2 Gene Knockdown by Western Blot Analysis 
SMAPIE-PEI-Gal micelleplexes transfection efficiency and Nrf2 gene 
knockdown in Hep G2 cells were evaluated using western blotting technique. Nrf2 
gene knockdown mediated by Nrf2 siRNA condensing SMAPIE-PEI-Gal 
micelleplexes was compared to that mediated by the positive transfection control 
Nrf2 siRNA condensing PEI 10 KDa polyplexes. As negative controls, siRNA 
Universal Negative Control #2 condensing micelleplexes and polyplexes were also 
prepared and tested. Briefly, all micelleplexes and polyplexes were prepared at 
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N/P ratio of 10 as described above in total volume of 100 µL of sterile 5% glucose 
solution containing 55 pmol siRNA. In 6 well plates, reverse transfection technique 
was applied for transfecting Hep G2 cells. In each well, 100 µL of the micelleplexes 
or the polyplexes were added, followed by the addition of 1 ml Hep G2 cells 
suspension in complete DMEM media supplemented with 10% FBS and 1% 
penicillin/streptomycin at cell density 500,000 cells/ml. The final siRNA 
concentration in each well was 50 nM. Plates were incubated under humidified 
conditions at 37 ̊C and 5% CO2 for 5 hours. After 5 hours of incubation, 1.1 ml fresh 
complete DMEM media was added in each well to obtain final volume of 2.2 ml 
and cells were incubated for additional 19 hours. Subsequently, cells were 
collected on ice in 15 ml centrifuge tubes, centrifuged at 4 ̊C, washed with ice cold 
1x PBS solution, and then centrifuged at 4 ̊C to get the cell pellet. Whole cell lysis 
buffer was then added to the cell pellets, and cells were lysed by pipetting up and 
down many times. Cells were incubated with the lysis buffer on an orbital rocker at 
4 ̊C for 30 minutes, then centrifuged at 120,000 rpm for 15 minutes at 4 ̊C. The 
pellet was discarded and the cell lysates were collected followed by quantification 
of the total protein concentration in each lysate by Bradford assay using BSA as 
standard.  
Samples were then prepared for loading in the 10% SDS-polyacrylamide 
gel, where lysates equivalent to 40 µg total protein were denatured by mixing with 
equal volume of 2x SDS-PAGE loading buffer containing β-mercaptoethanol 
followed by heating at 95 ̊C for 5 minutes. Denatured samples were then loaded 
on 10% SDS-polyacrylamide gel (SDS-PAGE) and proteins were separated by gel 
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electrophoresis at 120 volt for 2 hours. Once separated, the proteins were then 
transferred to nitrocellulose membrane at 100 volt for 1 hour on ice. The membrane 
was then blocked with 5% milk in TBST buffer at room temperature for 1 hour, then 
washed with TBST, and incubated overnight at 4 ̊C with 1:100 diluted Nrf2 (A-10) 
sc-365949 mouse monoclonal primary antibody in 5% BSA in TBST buffer. On the 
next day, the membrane was washed with TBST three times for 10 minutes each, 
followed by its incubation for 1 hour at room temperature with 1:2000 diluted goat 
anti-mouse IgG-HRP sc-2005 secondary antibody in 5% milk in TBST buffer. 
Finally, the membrane was washed in TBST three times, followed by detection of 
the bound secondary antibody HRP enzyme activity using chemiluminescent light 
based detection substrate (Super Signal West Pico chemiluminescent substrate) 
where the chemiluminescent immune reactive bands on the membrane were 
imaged using an ImageQuant LAS4000 (GE Healthcare Bio-sciences, Pittsburgh, 
PA, USA). Membranes were also probed with 1:500 diluted GAPDH (G-9) sc-
365062 mouse monoclonal primary antibody in 5% BSA in TBST buffer in a similar 
manner for detecting the GAPDH protein as a loading control. 
Western blot bands intensities were then quantified using Fiji ImageJ 
software (Life-Line version, 2015 December 22)133,134. According to previously 
published method, expression of Nrf2 protein reflected by the Nrf2 bands 
intensities was normalized to the expression of the GAPDH loading control protein 
of the same sample. Nrf2 Gene silencing efficiency was calculated by comparing 
the normalized intensity of Nrf2 of sample treated with siRNA targeting Nrf2 to the 
normalized intensity of Nrf2 of sample treated with negative control siRNA136. Data 
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from three independent experiments were shown as mean of normalized Nrf2 
intensity or mean of [normalized Nrf2 intensity / normalized Nrf2 intensity in 
negative control siRNA treated sample] (± standard deviation, n=3). Statistical 
analysis of data was completed through t-tests application using Vassar stats 
program.
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CHAPTER 3 RESULTS 
3.1. Synthesis and Characterization of SMAPIE-PEI-N3 and SMAPIE-PEI-Gal Micelles 
3.1.1 Synthesis of SMAPIE-PEI-N3 Micelles Forming Block Copolymer 
SMAPIE-PEI-N3 was synthesized in two steps by one-pot reaction (scheme 
3.1). In the first step, opening of the anhydride ring in SMAPIE copolymer (1) by 
primary amine group in the branched polymer polyethylenimine (PEI) (2) to form 
amide bond linking the two polymeric chains forming the di-block copolymer 
SMAPIE-PEI was undertaken. In the next step, conversion of some of primary 
amine groups in PEI to azide groups using Imidazole-1-sulfonylazide 
hydrochloride reagent as a “diazo donor”, and SMAPIE-PEI-N3 micelles forming 
block copolymer (3) was obtained as the final product. The diazo-transfer reaction 
was completed without any copper metal catalysis. Azide decorated micelles were 
subsequently reacted with alkyne group in strained cyclooctyne ring through 
copper free “click” chemistry. The final product purification was done through 
membrane dialysis. 
3.1.2 Synthesis of Targeting Ligand Conjugated SMAPIE-PEI-Gal Micelles Forming Block Copolymer 
Galactosamine targeted SMAPIE-PEI-Gal micelles forming block 
copolymer was synthesized by copper free “click” chemistry in two steps (scheme 
3.2). In the first step, the synthesis of the alkyne decorated galactosamine targeting 
ligand through coupling of N-hydroxysuccinimide part in DBCO-PEG5-NHS ester 
(4) with amine group in galactosamine.HCl (5) in its basic form was undertaken. 
The coupling reaction resulted in amide bond formation and galactosamino-PEG5-
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DBCO product (6) was obtained. In the second step, strain-promoted alkyne-azide 
cycloaddition (SPAAC) reaction was undertaken between galactosamino-PEG5-
DBCO product (6) from the first step and SMAPIE-PEI-N3 micelles forming block 
copolymer (3) to arrive at SMAPIE-PEI-Gal targeted micelles forming block 
copolymer (7). SPAAC is a well-established copper free “click” reaction between 
strained cyclooctyne moiety in product (6) and azide moiety in SMAPIE-PEI-N3 
block copolymer (3) forming a stable triazole ring linkage. The final product 
purification was done through membrane dialysis. 
Scheme 3.1. Synthesis of non-targeted SMAPIE-PEI-N3 micelles forming block copolymer (3)  
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Scheme 3.2. Synthesis of ligand targeted SMAPIE-PEI-Gal micelles forming block copolymer (7)  
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3.2 Size Exclusion Chromatography (SEC) 
Size exclusion chromatography was run to detect the relative molecular 
weight of the SMAPIE-PEI-N3 micelles compared to molecular weights of protein 
standards. The chromatogram of SMAPIE-PEI-N3 micelles is presented in figure 
3.1. The chromatogram shows unimodal molecular weight distribution. The elution 
volume of the micelles (78.14 mL) was used to calculate Ve/Vo (elution volume/ 
column void volume). The micelles relative molecular weight (13474.58 Da) was 
obtained from standard curve of 158 KDa, 44 KDa, 17 KDa and 1.35 KDa protein 
standards figure 3.2.  
 
Figure 3.1. Size exclusion chromatogram of SMAPIE-PEI-N3 micelles. 
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Figure 3.2. Standard curve of log molecular weights of protein standards versus standards Ve/Vo (elution volume/ column void volume), showing SMAPIE-PEI-N3 relative molecular weight determination.  
3.3 Copper Assay 
The relative concentration of PEI in the micelles was quantified by 
spectrophotometry, using a copper based assay. Copper ions successfully and 
specifically chelated primary amine groups in PEI polymer chains forming a blue 
colored complex called cuprammonium complex137. The intensity of the blue 
complex absorbance in the visible region was found to be in the linear range with 
the PEI 10 KDa various tested concentrations (2, 1, 0.5, 0.25, 0.125, 0.0625 
mg/ml). As illustrated in figure 3.3, cuprammonium complex absorbance intensities 
obtained at varying PEI concentrations were used to construct standard curve of 
PEI 10 KDa as a standard. The absorbance intensities of SMAPIE-PEI-N3 and 
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SMAPIE-PEI-Gal complexes were applied in the standard curve equation to 
determine their relative PEI composition. From the results, the PEI content was 
found to be 76.92 ± 3.23% (W/W) and 54.66 ± 5.9% (W/W) for SMAPIE-PEI-N3 
and SMAPIE-PEI-Gal, respectively.  
 
Figure 3.3. Standard curve of absorbance of cuprammonium complex at different PEI 10 KDa concentrations, showing PEI composition analysis of SMAPIE-PEI-N3 and SMAPIE-PEI-Gal micelles by copper assay.  
3.4 Determination of Critical Micelle Concentration (CMC) 
The ability of the amphiphilic block copolymer SMAPIE-PEI-N3 to form 
micelles in water was confirmed by fluorescence spectroscopy using pyrene as a 
fluorescent probe. Bathochromic shift in pyrene excitation wave length from 334 
nm to 339 nm with increasing SMAPIE-PEI-N3 copolymer concentration from 
0.0001 to 1mg/ml was detected (figure 3.4). The CMC of SMAPIE-PEI-N3 was 
found to be as low as 0.0112mg/ml which is ~ 8.6 х 10-7 M (figure 3.5).  
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Figure 3.4. Fluorescence spectra of pyrene at different SMAPIE-PEI-N3 concentrations in water, showing bathochromic shift in pyrene excitation wavelength with increasing SMAPIE-PEI-N3 concentration. 
 
Figure 3.5. Critical micelle concentration (CMC) Plot of I339/I334 emission ratio versus Log concentration of SMAPIE-PEI-N3 copolymer. 
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3.5 SYBER Gold Assay 
The siRNA condensation ability of non-targeted SMAPIE-PEI-N3, and 
targeted SMAPIE-PEI-Gal micelles was determined by SBYER Gold fluorescence 
quenching assay (figure 3.6). PEI 25 KDa and PEI 10 KDa polymers were also 
tested as controls for comparison. Significant SBYER Gold dye fluorescence 
quenching indicates efficient siRNA condensation. Complete condensation of the 
siRNA was shown in targeted SMAPIE-PEI-Gal and non-targeted SMAPIE-PEI-
N3 micelleplexes at and above N/P ratio of 4 and 7, respectively. Both PEI 25 KDa 
and PEI 10 KDa polymers were able to achieve complete siRNA condensation at 
N/P ratio of 4 and higher. Non-targeted SMAPIE-PEI-N3 micelles showed lesser 
siRNA complexation efficiency compared to targeted SMAPIE-PEI-Gal micelles 
and PEI polymers at N/P ratios lower than 10. The siRNA condensation capacity 
of all micelleplexes and polyplexes increased with increasing N/P ratio.  
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Figure 3.6. Condensation/Complexation behavior of polymers or micelles to siRNA by SYBER Gold fluorescence quenching assay at increasing N/P ratios.  
3.6 Size and Zeta Potential Measurements: Light Scattering (LS) 
Light scattering analysis was performed for determining the hydrodynamic 
size and zeta potential of plain SMAPIE-PEI-N3 (without siRNA), plain SMAPIE-
PEI-Gal micelles (without siRNA) and siRNA containing targeted and non-targeted 
micelles (micelleplexes) as well as PEI 10 KDa polyplexes. Results were 
presented as mean (± standard deviation) from three independent experiments. 
Figure 3.7.A, illustrates that SMAPIE-PEI-Gal micelles exhibited larger 
hydrodynamic diameter of 240 ± 4.05 nm than SMAPIE-PEI-N3 micelles whose 
size was around 160 ± 1.5 nm. As shown in figure 3.7.B, both SMAPIE-PEI-N3 
and SMAPIE-PEI-Gal micelles had high zeta potential of around 38 mV ± 0.76 and 
40 ± 0.67 mV, respectively. As summarized in table 3.1, polydispersity index (PDI) 
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as an indication of size distribution of SMAPIE-PEI-N3 and SMAPIE-PEI-Gal 
micelles was found to be 0.25 ± 0.01 and 0.42 ± 0.03, respectively. Large particle 
sizes were observed at micelleplexes and polyplexes formed at lower N/P ratios, 
at N/P ratio < 7 for SMAPIE-PEI-N3 micelleplexes and at N/P ratio of 3 in case of 
PEI polyplexes and SMAPIE-PEI-Gal micelleplexes. Apart from that, all the 
polyplexes and micelleplexes were around 200 nm (figure 3.8). Zeta potential of 
all micelleplexes and polyplexes was increased with increase in N/P ratios, with 
maximum zeta potential of around 23 mV at N/P ratio of 10, in case of both targeted 
and non-targeted micelleplexes (figure 3.9). Table 3.2 shows that the PDI (with its 
standard deviation) was increased mostly in the case of loosely formed large sized 
micelleplexes/polyplexes.  However, the PDI of micelleplexes at and above N/P 
ratio of 7 for SMAPIE-PEI-N3 and N/P ratio of 4 for SMAPIE-PEI-Gal was ≤ 0.39, 
indicating compact micelleplexes formation.  
 
Figure 3.7. Hydrodynamic diameters (A) and zeta potentials (B) of plain SMAPIE-PEI-N3 and SMAPIE-PEI-Gal micelles. 
A) B) 
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Table 3.1. Polydispersity indexes of plain SMAPIE-PEI-N3 and SMAPIE-PEI-Gal micelles. Results are presented as average from three independent samples (n=3) ± standard deviation. 
Micelles polydispersity index (Mean ± Standard deviation, n =3) 
SMAPIE-PEI-N3 SMAPIE-PEI-Gal 
0.25 ± 0.01 0.42 ± 0.03  
 
Figure 3.8. Hydrodynamic diameters of SMAPIE-PEI-N3/siRNA, SMAPIE-PEI-Gal/siRNA micelleplexes and PEI 10 KDa/siRNA polyplexes at the specified N/P ratios. 
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Figure 3.9. Zeta potentials of SMAPIE-PEI-N3/siRNA, SMAPIE-PEI-Gal/siRNA micelleplexes and PEI 10 KDa/siRNA polyplexes at the specified N/P ratios. 
Table 3.2. Polydispersity indexes of SMAPIE-PEI-N3/siRNA, SMAPIE-PEI-Gal/siRNA micelleplexes and PEI 10 KDa/siRNA polyplexes at the specified N/P ratios. Results are presented as average from three independent samples (n=3) ± standard deviation. 
 Polydispersity index (Mean ± Standard deviation, n =3) 
 Micelleplexes Polyplexes 
N/P ratio SMAPIE-PEI-N3 SMAPIE-PEI-Gal PEI 10 KDa 
N/P = 3 0.2 ± 0.08 0.44 ± 0.49 0.49 ± 0.36 
N/P = 4 0.34 ± 0.02 0.23 ± 0.09 0.28 ± 0.14 
N/P = 5 0.22 ± 0.28 0.26 ± 0.03 0.35 ± 0.03 
N/P = 7 0.34 ± 0.12 0.39 ± 0.03 0.31 ± 0.09 
N/P = 10 0.34 ± 0.1 0.25 ± 0.11 0.45 ± 0.26 
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3.7 Size and Morphology Measurements: Transmission Electron Microscopy (TEM) 
TEM images illustrated the size and morphology of plain micelles (without 
siRNA) and micelleplexes (with siRNA) in the dry state (figure 3.10). Globular 
compact structure of darkly stained shell and white (unstained) core was obvious. 
SMAPIE-PEI-N3 and SMAPIE-PEI-Gal micelles (without siRNA) were of size   ̴ 100 
nm and   ̴ 200 nm, respectively. At N/P ratio of 10, non-targeted micelleplexes 
displayed a size of   ̴ 160 nm, while galactosamine targeted micelleplexes 
displayed a size of   ̴ 130 nm. The TEM size, in the dry state, were relatively smaller 
than the ones obtained from DLS measurements, which is the hydrodynamic size.   
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Figure 3.10. Transmission electron microscopy images illustrating size and morphology of SMAPIE-PEI-N3 micelles (without siRNA) (A and B), SMAPIE-PEI-Gal micelles (without siRNA) (C and D), SMAPIE-PEI-N3 micelleplexes (E), and SMAPIE-PEI-Gal micelleplexes (F). Micelleplexes were prepared at N/P ratio of 10. Micelles and micelleplexes were negatively stained with 3% uranyl acetate stain. 
3.8 Buffering Capacity Measurements 
The ability of polycationic vectors to escape out of endosomes and release 
their cargo into the cell cytoplasm is an important property for intracellular siRNA 
release and can be determined by their buffering capacity100. The buffering 
A) C) 
B) D) 
E) F) 
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capacity is evaluated by the amount of protons required for reducing pH in the 
endosomal pH range of (7-5.5)138. An acid-base titration experiment was 
performed to estimate buffering abilities of SMAPIE-PEI-N3 and SMAPIE-PEI-Gal 
micelles in comparison to PEI polymers and 150 mM NaCl solution (figure 3.11). 
During acid titration, small pH changes were observed in case of all PEI polymers, 
as well as, SMAPIE-PEI-N3 and SMAPIE-PEI-Gal micelles, while 150 mM NaCl 
solution showed an opposite scenario of abrupt pH drop. All titration curves of PEI 
polymers, SMAPIE-PEI-N3 and SMAPIE-PEI-Gal micelles showed two inflection 
points at pH ranges of (11-9) and (7-5.5). SMAPIE-PEI-N3 micelles titration data 
illustrated that they had a little lower proton buffering ability than SMAPIE-PEI-Gal 
micelles and PEI polymers of different molecular weights. On the other hand, 
SMAPIE-PEI-Gal micelles showed comparable buffering capacity to that of PEI 
polymers. 
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Figure 3.11. Acid base titration profile of non-targeted SMAPIE-PEI-N3, targeted SMAPIE-PEI-Gal micelles forming block copolymers and PEI polymers of different molecular weights (25, 10, 1.8 KDa) at pH range (11-2). 
3.9 Biological Evaluation of SMAPIE-PEI-N3 and SMAPEI-PEI-Gal Micelles 
3.9.1 Cytotoxicity Assay Using Human Liver Cancer Cells 
The in vitro cytotoxicity of PEI polymers, non-targeted SMAPEI-PEI-N3, and 
targeted SMAPEI-PEI-Gal micelles was investigated in HepG2 cells. Results 
demonstrated the following order: SMAPEI-PEI-Gal < PEI 10 KDa < SMAPEI-PEI-
N3 < PEI 25 KDa for their cytotoxicity and inhibitory concentration IC50 (figure 3.12). 
IC50 values were found to be approximately 12, 70, 130, and 240 µg/mL for PEI 25 
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KDa, SMAPEI-PEI-N3, PEI 10 KDa, and SMAPEI-PEI-Gal, respectively after 48 
hours of incubation with cells. Cell viability was more than 80% in case of SMAPEI-
PEI-N3, SMAPEI-PEI-Gal, and PEI 10 KDa at concentration below 20 µg/mL.  
 
Figure 3.12. Plot showing cytotoxicity analysis of SMAPIE-PEI-N3, and SMAPIE-PEI-Gal copolymers in comparison with PEI 25 KDa and PEI 10 KDa as polymeric controls. Analysis was done on Hep G2 cells by MTT assay with concentration range (0 – 400 µg/mL) and incubation time of 48 hours. 
3.9.2 Cellular Uptake Quantification by Flow Cytometry 
SMAPIE-PEI-N3 or SMAPIE-PEI-Gal micelleplexes, and PEI 10 KDa 
polyplexes were prepared with fluorescent FAM-labeled siRNA at N/P ratio of 10 
to evaluate and quantify their differential uptake into asialoglycoprotein receptor 
(ASGPR) positive Hep G2 cells. As shown in figure 3.13.A, after 5 hours incubation 
of the different samples with Hep G2 cells, the amount of siRNA-carrier complexes 
internalized into cells as reflected by the detected fluorescence intensity was in the 
following order : SMAPIE-PEI-Gal micelleplexes ˃ SMAPIE-PEI-N3 micelleplexes 
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˃ PEI 10 KDa polyplexes ˃ free FAM-labeled siRNA ˃ untreated cells. Figure 
3.13.B, demonstrates that the cellular uptake associated fluorescence intensity for 
SMAPIE-PEI-Gal micelleplexes in presence of 20 mM free galactosamine as 
competitor for ASGPRs was lower when compared to the intensity for SMAPIE-
PEI-Gal micelleplexes samples lacking free galactosamine.  
Statistical analysis of cellular uptake Median fluorescent intensity 
measurements for all the samples was summarized in figure 3.14. Data revealed 
no significant difference in fluorescence from free FAM-labeled siRNA cellular 
uptake compared to blank untreated cells. Cellular uptake of SMAPIE-PEI-N3 
micelleplexes was also not significantly different from that of the positive control 
PEI 10 KDa polyplexes. However, targeted SMAPIE-PEI-Gal micelleplexes 
achieved significant increase in cellular uptake as compared to both non-targeted 
SMAPIE-PEI-N3 micelleplexes and PEI 10 KDa polyplexes (p ˂ 0.01) with 0.84 
and 1.2 fold increase, respectively. The presence of free galactosamine 
competitor, significantly decreased the targeted SMAPIE-PEI-Gal micelleplexes 
cellular internalization by 0.32 fold.  
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Figure 3.13. Histogram of flow cytometry analysis showing number of cells/channel on Y- axis versus the fluorescence intensity detected from FAM-labeled siRNA positive Hep G2 cells. A) Shows compared fluorescence intensity achieved at cellular uptake of SMAPIE-PEI-Gal or SMAPIE-PEI-N3 micelleplexes prepared with FAM-labeled siRNA, to that achieved in case of PEI 10 KDa polyplexes (positive control) and free FAM-labeled siRNA as well as untreated cells (negative controls). B) Shows different cellular uptake associated fluorescence intensity for SMAPIE-PEI-Gal micelleplexes in presence or absence of 20 Mm free galactosamine as competitor.  
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Figure 3.14. Plot of median fluorescent intensity of FAM- labeled siRNA positive Hep G2 cells for quantitative determination of cellular uptake of SMAPIE-PEI-N3, SMAPIE-PEI-Gal micelleplexes or polyplexes prepared with FAM-labeled siRNA at N/P ratio of 10. PEI 10 KDa polyplexes were used as positive control, while free FAM-labeled siRNA and untreated cells were as negative controls. As a competitive assay, SMAPIE-PEI-Gal micelleplexes uptake in the presence of 20 mM free galactosmine as a competitor of galactosamine in SMAPIE-PEI-Gal was detected. Results were obtained after 5 hours incubation of samples with cells, and are presented as (mean ± standard deviation of n=3, ** p ˂ 0.01, ns = none statistically significant). 
3.9.3 Cellular Uptake and Endosomal Escape by Confocal Laser Scanning Microscopy (CLSM) 
Confocal laser scanning microscopy was performed to see the ability of 
targeted SMAPIE-PEI-Gal and non-targeted SMAPIE-PEI-N3 micelleplexes to 
deliver siRNA into asialoglycoprotein receptor (ASGPR) positive Hep G2 cells as 
well as to determine route of their cellular uptake. PEI 10 KDa polyplexes were 
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used as positive control. Competition assay was conducted to study ASGPR 
targeting ability of SMAPIE-PEI-Gal micelleplexes in absence and presence of free 
galactosamine. All micelleplexes or polyplexes used for Hep G2 cells transfection 
were prepared with FAM-labeled siRNA at N/P ratio of 10. Live cell images were 
obtained 22 hours post transfection.  
As shown in figure 3.15, the Hep G2 cells nuclei were stained with Hoechst 
33342 stain (blue) in first row, acidic endosomal compartments with Lyso Tracker 
Deep Red dye (red) in second row, and FAM labeled siRNA (green) in third row. 
Results showed more green fluorescent siRNA within Hep G2 cell when treated 
with galactosamine targeted SMAPIE-PEI-Gal micelleplexes than with non-
targeted SMAPIE-PEI-N3 micelleplexes or the positive control PEI 10 KDa 
polyplexes. In the competition assay, less green fluorescence per cell was seen in 
cells treated with SMAPIE-PEI-Gal micelleplexes in presence of free 
galactosamine compared to ones lacking free galactosamine.  Although, most of 
the green fluorescence from the siRNA was found in the cells cytoplasm around 
the blue nucleus, however little amount was still co-localized with the acidic 
endosomes as demonstrated by yellow colored spots in merged images in fourth 
row. As illustrated in figure 3.16, mean of total corrected cellular fluorescence 
(TCCF) was calculated to quantify the green fluorescent siRNA internalized in cells 
with each treatment. TCCF was estimated for each cell, then the mean of all 
TCCFs for all cells / image was obtained. The results were found to be consistent 
with the ones obtained by flow cytometry quantification as mentioned above. 
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Figure 3.15. Confocal laser scanning microscopy images of Hep G2 cells treated with SMAPIE-PEI-Gal micelleplexes (column A), SMAPIE-PEI-Gal micelleplexes plus free galactosamine competitor (column B), SMAPIE-PEI-N3 micelleplexes (column C) and PEI 10 KDa polyplexes (column D), 22 hours after transfection. Micelleplexes or polyplexes were prepared with FAM-labeled siRNA at N/P ratio of 10. The cells nuclei were stained with Hoechst 33342 stain (blue), acidic endosomal compartments with Lyso Tracker Deep Red dye (red), and siRNA was labeled with FAM (green). 
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Figure 3.16. Plot illustrating CLSM images green fluorescence quantification. Mean total corrected cellular fluorescence (MTCCF) of internalized green fluorescent FAM -labeled siRNA complexed with micelleplexes or polyplexes in Hep G2 cells was calculated per image and plotted on Y axis against treatment type on X axis.  
3.9.4 Transfection Efficiency and Nrf2 Gene Knockdown by Western Blot Analysis  SMAPIE-PEI-Gal micelleplexes or PEI 10 KDa polyplexes condensing 55 
pmol Universal Negative Control siRNA (as negative control) or Nrf2 siRNA at N/P 
ratio of 10, were prepared and used for transfecting Hep G2 cells by reverse 
transfection technique. After 24 hours of transfection, Western blot protein 
expression analysis was performed to determine and quantify Nrf2 gene 
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knockdown mediated by SMAPIE-PEI-Gal micelleplexes compared to the positive 
transfection control PEI 10 KDa polyplexes.  
As illustrated in figure 3.17, both Nrf2 complexing SMAPIE-PEI-Gal 
micelleplexes and PEI 10 KDa polyplexes mediated statistically significant Nrf2 
gene knockdown (p ˂ 0.05). Nrf2 protein expression in cells treated with Nrf2 
condensing SMAPIE-PEI-Gal micelleplexes was 0.49 fold lower than cells treated 
with negative control siRNA condensing SMAPIE-PEI-Gal micelleplexes. Similarly, 
Nrf2 protein expression in cells treated with Nrf2 condensing PEI 10 KDa 
polyplexes was 0.27 fold lower than cells treated with negative control siRNA 
condensing PEI 10 KDa polyplexes. However, the Nrf2 gene knockdown mediated 
by SMAPIE-PEI-Gal micelleplexes was 21% higher than that mediated by PEI 10 
KDa polyplexes (p ˂ 0.05). 
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Figure 3.17. Western blot bands of Nrf2 and GAPDH protein levels detected in Hep G2 cells after 24 hours transfection with SMAPIE-PEI-Gal micelleplexes or PEI 10 KDa polyplexes condensing 50 nM Nrf2-siRNA or negative control siRNA (NCr-siRNA) at N/P ratio of 10 (A). Estimation of Nrf2 gene silencing efficiency accomplished by SMAPIE-PEI-Gal micelleplexes versus PEI 10 KDa polyplexes through quantification of the above western bands intensities, data presented as mean of (GAPDH normalized Nrf2 protein level/GAPDH normalized Nrf2 protein level in case of NCr-siRNA plexes treatment) ± standard deviation, n=3, and * p ˂ 0.05 statistical significance (B).
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CHAPTER 4 DISCUSSION 
4.1 Synthesis and Characterization of SMAPIE-PEI-N3 and SMAPIE-PEI-Gal Micelles 
4.1.1 Synthesis of SMAPIE-PEI-N3 Micelles Forming Block Co-polymer 
SMAPIE-PEI-N3 micelles forming block co-polymer was synthesized from 
SMAPIE 2.3 KDa copolymer and branched PEI 10 KDa polymer. PEI polymer of 
moderate molecular weight and optimal number of cationic groups was chosen for 
the synthesis since it has better nucleic acids condensation and transfection 
efficiency than the lower molecular weight ones and at the same time it induces 
lesser cytotoxicity compared to higher molecular weight PEI chains139. SMAPIE 
copolymer has hydrophobic styrene groups and iso-octyl chains that can help in 
self-assembly and formation of the micelles by hydrophobic interactions.   
SMAPIE-PEI-N3 micelles forming block co-polymer was synthesized in two 
steps by one-pot reaction. The one-pot reaction module afforded several 
advantages including faster and easier product synthesis, lesser purification steps 
(no necessary purification of the intermediate and only purification was done for 
the final product), and hence enabled better product yield. In the first step, SMAPIE 
and PEI were reacted in equimolar ratio to give a water soluble diblock-copolymer. 
It was noted that increasing the molar ratio of SMAPIE compromised the water 
solubility of the so-formed diblock-copolymer. In the second step, partial 
conversion of primary amine groups in PEI to azide groups was achieved in order 
to create azide moieties for targeting ligands attachment through strain promoted 
alkyne azide cycloaddition (SPAAC) “click” reaction (figure 4.1), while at the same 
time preserving good share of the cationic amine groups for siRNA or gene 
63  
  
condensation and delivery. It is important to note that we succeeded to complete 
the diazo-transfer reaction without copper metal catalysis compared to what was 
previously published126. In addition, targeting ligand attachment to the block co-
polymer was completed using copper free “click” synthesis in order to avoid copper 
metal difficult purification and biological toxicity associated with trace metal 
impurities in the final product.  
 
Figure 4.1. Illustration of targeting ligand attachment to SMAPIE-PEI-N3 micelles via strain promoted alkyne azide cycloaddition (SPAAC) “click” reaction. 
The successful synthesis of SMAPIE-PEI-N3 product was confirmed by 
FT/IR and 1H NMR spectroscopy. FT/IR spectra (figure 4.2) showed the absence 
of the anhydride –C=O characteristic antisymmetric and symmetric stretch peaks 
in SMAPIE-PEI-N3 at 1859 cm-1 and1776 cm-1 respectively with the appearance 
of the secondary amide–C=O stretch at 1671 cm-1 indicating anhydride ring 
opening in SMAPIE and formation of the amide bond linker between the two 
polymeric chains. In addition, the azide –N3   stretch at 2105 cm-1 confirmed the 
diazo-transfer reaction. 
1H NMR spectra (figure 4.3) further supported the SMAPIE-PEI-N3 
copolymer synthesis. 1H NMR spectra of unreacted SMAPIE and PEI chains were 
presented in figure 4.3.A and figure 4.3.B, respectively. 1H NMR spectrum of 
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separately synthesized PEI-N3 (figure 4.3.C) illustrated the occurrence of partial 
azido modification of PEI chain without any other side reactions. PEI protons on 
carbons adjacent to unmodified amine groups (-CH2CH2NH-) were at chemical 
shift 2.2-3 ppm, while the protons on carbons adjacent to azide groups (-
NHCH2CH2N3) and (-NHCH2CH2N3) were at chemical shift of 3 ppm and 3.3 ppm, 
respectively. As shown in figure 4.3.D, 1H NMR spectrum of isolated SMAPIE-PEI 
product of the one pot reaction first step indicated grafting of SMAPIE on PEI chain. 
PEI (-CH2CH2NH-) characteristic peak at chemical shift 2.2-3 ppm, overlapping 
peaks of (-COCH- and -OCH2- in SMAPIE copolymer, and -CH2NHCO-  in PEI 
chain) at 3.1-3.5 ppm, and the SMAPIE (C6H5-) peak in cumene terminal and 
styrene residues at 6.4-7.4 ppm were obviously detected. 1H NMR spectrum of 
SMAPIE-PEI-N3 (figure 4.3.E) showed the PEI (-CH2CH2NH-) characteristic peak 
at chemical shift 2.2-3 ppm, overlapping peaks of (-COCH- and -OCH2- in SMAPIE 
copolymer, -CH2NHCO- and -NHCH2CH2N3  in PEI chain) at 3.1-3.6 ppm, and the 
SMAPIE (C6H5-) peak in cumene terminal and styrene residues at 6.4-7.4 ppm. 
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Figure 4.2. FT/IR spectra of PEI polymer (green), SMAPIE copolymer (blue), and SMAPIE-PEI-N3 micelles forming block copolymer (red).  
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Figure 4.3. 1H NMR spectra of (A) SMAPIE in DMSO (B) PEI in D2O (C) PEI-N3 in D2O (D) SMAPIE-PEI in CD3OD (E) SMAPIE-PEI-N3 in CD3OD. 
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4.1.2 Synthesis of Targeting Ligand Conjugated SMAPIE-PEI-Gal Micelles Forming Block Copolymer 
SMAPIE-PEI-Gal (galactosamine targeted micelles forming block co-
polymer) was synthesized using copper free “click” chemistry in essence to obtain 
biocompatible micelles that can target ASGPR in hepatocellular carcinoma. During 
the first step, galactosamine as a targeting ligand was linked via amide bond to 
DBCO-PEG5 moiety by amine reactive NHS coupling chemistry. The presence of 
PEG moiety in DBCO-PEG5-NHS ester helped to improve its water solubility and 
hence its reactivity. Galactosamine was added in three fold excess compared to 
DBCO-PEG5-NHS ester to ensure complete ester modification by the end of the 
reaction. Galactosamino-PEG5-DBCO (targeting) blocks was then attached to 
SMAPIE-PEI-N3 micelles using copper free “click” chemistry.  
“Click” chemistry as a synthetic tool has been extensively studied in the 
previous years and has several advantages including high selectivity, high reaction 
yield, high efficiency, fast reaction rate, mild reaction conditions and water 
compatibility108. “Click” chemistry, either copper catalyzed or copper free, has been 
used in many applications including polymer synthesis140,141, and conjugation of 
imaging agents or targeting ligands on nanosystems142,143. Copper free 
cycloaddition approach has also been used in liposomes functionalization144, DNA 
conjugation to nanoparticles145, and biorthogonal biomolecules labeling in living 
cells both in vitro and in vivo146. One major advantage of the copper free approach 
over the copper catalyzed one is the biocompatibility and absence of toxicity for 
living cells since cyclooctyne ring strain is the primary reaction promotor instead of 
the cytotoxic copper metal catalyst. Such reactions can thus be carried out without 
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the need for purification or removal of copper and highly useful for biological 
applications. 
Successful synthesis of biocompatible SMAPIE-PEI-Gal was verified using 
1H NMR spectra as shown in figure 4.4. The unreacted galactosamine protons 
characteristic peaks are illustrated in figure 4.4.A. 1H NMR spectrum of SMAPIE-
PEI-Gal co-polymer is presented in figure 4.4.B. In addition to the characteristic 
peaks in SMAPIE-PEI-N3 mentioned above (figure 4.3.E), galactosamino-PEG5-
DBCO attachment was confirmed by the presence of the following peaks: (-CHNH2 
) protons in galactosamine alpha and beta anomers and (-OCH2CH2O-) in PEG 
chain at 3-3.49 ppm, (-CHCHOH, -CH2OH, -CHCH2-) protons in galactosamine 
alpha and beta anomers at 3.5-4 ppm, (-OCHOH alpha and beta anomeric 
protons) in galactosamine at 4.5, 5 ppm, overlapping peaks of (-C6H4 in substituted 
DBCO and -C6H5 in cumene terminal and styrene residues) at 6.4-7.6 ppm.  
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Figure 4.4. 1H NMR spectra of (A) Galactosamine in D2O (B) SMAPIE-PEI-Gal in D2O. 
4.2 Size Exclusion Chromatography (SEC) 
Size exclusion chromatography was run to detect the molecular weight of 
the SMAPIE-PEI-N3 micelles relative to molecular weights of standards. Gel 
filtration chromatography was chosen as the experimental method since SMAPIE-
PEI-N3 micelles are water soluble.  
The chromatogram of SMAPIE-PEI-N3 micelles (figure 3.1) revealed 
unimodal molecular weight distribution, indicating that the micelles were of uniform 
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size with low polydispersity index. The relative molecular weight of micelles 
obtained by substitution in the standard curve equation (figure 3.2) was 13474.58 
Da. Although the molecular weight obtained is relative and not an absolute one, it 
nonetheless gave a good estimation of the micelle composition. From the 
molecular weight estimation, it can be concluded that only one chain of the 2.3 
KDa SMAPIE copolymer got grafted to one chain of the 10 KDa PEI polymer in 
addition to the molecular weight increase as a result of partial amine groups 
modification to azide groups. This conclusion was in agreement with what was 
expected based on the polymers composition and the equimolar ratio at which the 
synthesis was performed. According to copolymer composition information 
provided by the manufacturer, SMAPIE copolymer has a molar ratio of 4:1 of 
styrene to anhydride units, and 75% of the anhydride rings are esterified. Molar 
ratio calculations indicated that each SMAPIE copolymer chain contained 
approximately 3 opened and 1 unopened anhydride rings. Thus, presence of only 
1 unopened anhydride ring in each SMAPIE copolymer chain prevents the grafting 
of more than one PEI polymer chain on the same SMAPIE copolymer chain, which 
helped to reduce polydispersity and chances of crosslinking. 
4.3 Copper Assay 
PEI is a cationic polymer that has been well studied for condensing 
negatively charged siRNAs. The role of PEI in both non-targeted SMAPIE-PEI-N3 
and ASGP receptor targeted SMAPIE-PEI-Gal micelles is mainly for gene/siRNA 
complexation. The exact content of PEI is essential for correct calculation of 
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micelles amount necessary for micelleplexes formation at the desired amine 
groups in polymer/phosphate groups in nucleic acids (N/P) ratio.  
The PEI concentration in micelles forming block co-polymer was quantified 
through spectrophotometry by copper chelate formation. According to pervious 
reports, copper ions form specific blue cuprammonium complex with primary 
amine groups in PEI polymer137.  The intensity of so-formed blue color is a 
reflection of the PEI concentration as long as the conditions for beer-lambert laws 
were followed. PEI chains in both SMAPIE-PEI-N3 and SMAPIE-PEI-Gal co-
polymers are the only regions containing primary amine groups, and hence 
accurate quantification of PEI composition in both micelles can be done using 
copper chelation, without any interference.  
As shown in figure 3.3, PEI content in SMAPIE-PEI-Gal micelles was lower 
than in SMAPIE-PEI-N3 micelles because of the extra galactosamino-PEG5-
DBCO moieties in SMAPIE-PEI-Gal co-polymer. In line with the size exclusion 
chromatography, copper assay results also confirmed that only one chain of 
SMAPIE copolymer was grafted to one chain of PEI in SMAPIE-PEI-N3 and 
SMAPIE-PEI-Gal co-polymers.  
4.4 Determination of Critical Micelle Concentration (CMC) 
The estimation of critical micelle concentration using pyrene as a 
fluorescent hydrophobic probe, is a way to confirm the ability of amphiphilic 
copolymers to form micelles. Amphiphilic copolymers are usually block co-
polymers composed of hydrophilic and hydrophobic moieties that self-assemble in 
aqueous environment into micellar spherical core-shell structure, at concentration 
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exceeding the critical micelle concentration80. When CMC is reached in aqueous 
environment, the hydrophobic moieties of the amphiphilic copolymer start to 
associate with each other and away from water to reach more favorable entropy 
forming the micellar core while the hydrophilic moieties form the micellar shell82. 
According to the SMAPIE copolymer composition information and based on 
molar ratio calculations, each SMAPIE chain contained around 17 styrene groups, 
3 opened and 1 unopened anhydride rings. The big number of the styrene 
hydrophobic rings (17) together with the iso-octyl aliphatic chains esterified with 
the open anhydride rings participated in creation of the hydrophobic core of the 
SMAPIE-PEI-N3 micelles, while hydrophilic PEI polymeric chain formed the shell. 
 Pyrene is a fluorescent hydrophobic probe whose excitation wavelength 
vary depending on the hydrophobicity of the surrounding environment, where it is 
lower in a hydrophilic environment than in a hydrophobic one147. Bathochromic 
shift in pyrene excitation wave length from 334 nm to 339 nm with increasing 
SMAPIE-PEI-N3 copolymer concentration indicated pyrene presence in the 
hydrophobic core of the formed micelles when CMC was exceeded (figure 3.4).It 
was reported that micelles of CMC in order of 10-6-10-7 M increase the blood 
circulation time of their cargo as they have good stability in vivo84. SMAPIE-PEI-
N3 micelles was formed at low concentration and CMC was in the 10-7 M range 
which indicates that SMAPIE-PEI-N3 micelles are good candidates for in vivo 
drug/gene delivery and can have good stability profile for in vivo applications. 
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4.5 SYBER Gold Assay 
Optimal nucleic acids complexation ability is a prerequisite for non-viral 
gene/siRNA vectors to achieve required gene/siRNA protection and effective 
cellular transfection148. Polymeric vectors based nucleic acids complexation can 
be evaluated using SYBER Gold assay.  
SYBER Gold is a fluorescent dye that binds to both free and uncondensed 
siRNA and emits fluorescence, the more the siRNA gets condensed and 
sequestered in the micelleplexes or polyplexes the less the free siRNA available 
to bind to the dye and the more its fluorescence quenching149,150.  
As shown in figure 3.6, the siRNA complexation capacity of all micelleplexes 
and polyplexes increased with increasing the N/P ratio. The reason is that, nucleic 
acids complexation with micelles or polymers occur through electrostatic 
interaction between negatively charged phosphate groups in nucleic acids and 
cationic groups in PEI polymeric units. As the N/P ratio increases, total cationic 
charge increases which allow better ionic interaction and more efficient siRNA 
condensation131. Non-targeted SMAPIE-PEI-N3 micelles showed lesser siRNA 
complexation efficiency compared to PEI polymers. It may be attributed to the 
presence of the negatively charged carboxylate groups in SMAPIE copolymer. 
According to previous study, carboxylate anions can diminish the electrostatic 
binding of nucleic acids to polycations138. Strikingly, galactosamino-PEG5 moieties 
didn’t hinder or weaken the siRNA access and ionic interaction with PEI segments 
in SMAPIE-PEI-Gal micelles, but instead, the targeted micelles showed 
comparable siRNA condensation capacity to PEI polymers. It was previously 
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reported that carbohydrates can form hydrogen bonding with nucleic acids and 
increase their complexation efficiency in polyplexes148.One possible explanation, 
in line with previous report, is that galactosamine carbohydrate residues might 
have an important role in improved SMAPIE-PEI-Gal micelles condensation ability 
by formation of hydrogen bonding with siRNAs.  
4.6 Size and Zeta Potential Measurements: Light Scattering (LS)  
The amphiphilic nature of SMAPIE-PEI-N3 and SMAPIE-PEI-Gal co-
polymers enabled them to self-assemble to form nanomicelles spontaneously in 
aqueous solution. The micelles can condense siRNA forming micelleplexes.  Both 
particle size and surface charge (or zeta potential) are important aspects that affect 
particles cytotoxicity, localization,  cellular uptake and transfection efficiency151,152. 
Small particles achieve better cellular uptake, and moderate positive zeta potential 
decreases particles aggregation and increases their colloidal stability without being 
highly cytotoxic149,153.   
Hydrodynamic sizes of plain micelles (without loaded siRNA) and siRNA 
containing micelles (micelleplexes), and polyplexes were measured using dynamic 
light scattering (DLS) technique, while their zeta potentials were determined by 
electrophoretic light scattering (ELS). As shown in figure 3.7.A, hydrodynamic 
diameter of SMAPIE-PEI-Gal micelles was found to be larger than that of SMAPIE-
PEI-N3 micelles, due to the presence of additional galactosamino-PEG5 moieties. 
Figure 3.7.B illustrated that, both SMAPIE-PEI-Gal and SMAPIE-PEI-N3 micelles 
had high zeta potential of around 40 mV because of the cationic amino groups 
present in the PEI chain. However, siRNA complexation with both micelles 
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neutralized large portion of their cationic charge and hence decreased their 
cytotoxicity. In figure 3.8, micelleplexes and polyplexes formed at lower N/P ratios 
exhibited larger particle sizes as compared to the ones formed at higher N/P ratios, 
till complete siRNA condensation is realized154, where a size of 200 nm is noted. 
As presented in figure 3.9, all micelleplexes and polyplexes showed similar trend 
of increasing zeta potential as N/P ratio increases, which is in line with previously 
published reports132,143. Larger particle sizes as well as negative zeta potential 
indicated inefficient and loose siRNA condensation149. N/P ratio of 7 for SMAPIE-
PEI-N3 and 4 for SMAPIE-PEI-Gal micelleplexes, seemed to be the most optimal 
N/P ratios, where the particles had the smaller size together with lesser positive 
surface charge. Micelleplexes and polyplexes prepared at N/P ratio of 10 were 
thus chosen for further experiments to allow data comparison.  
As demonstrated in tables 3.1 and 3.2, micelles and micelleplexes with 
efficient siRNA sequestering were of moderate size distribution with PDI ≤ 0.42. 
However, higher PDI was obtained at improper siRNA complexation due to the 
formation of loose aggregates with larger size. 
4.7 Size and Morphology Measurements: Transmission Electron Microscopy (TEM) 
Size and morphology of plain micelles and micelleplexes were determined 
in the dry state by transmission electron microscopy (TEM). Micelles and 
micelleplexes presented spherical Core/Shell structure (figure 3.10) similar to 
previously published results94,155. The core/shell structure presented further 
confirmed the ability of the amphiphilic SMAPIE-PEI co-polymer to self-assemble 
into micelles in aqueous environment, where the hydrophobic styrene rings and 
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iso-octyl chains of SMAPIE arranged to form the white/unstained core93 and the 
hydrophilic amine groups of PEI occupied the outer shell with the dark stain. In line 
with earlier publication, the styrene residues aromatic interaction contributed to the 
formation of uniform and tightly packed dense micellar core that was more resistant 
to water infiltration93.  
SMAPIE-PEI-Gal micelles showed larger size ( ̴ 200 nm) than SMAPIE-PEI-
N3 micelles ( ̴ 100 nm) due to the excess molecular weight of galactosamino-PEG5 
moieties in SMAPIE-PEI-Gal micelles. In contrast, the SMAPIE-PEI-Gal 
micelleplexes exhibited smaller size than SMAPIE-PEI-N3 micelleplexes, probably 
due to more efficient packaging/condensation of siRNA in SMAPIE-PEI-Gal 
micelleplexes than in SMAPIE-PEI-N3 micelleplexes.  
In the case of SMAPIE-PEI-N3 and SMAPIE-PEI-Gal micelles and 
micelleplexes, TEM sizes were of similar pattern with the ones obtained from DLS 
measurements, however they were noted to be smaller in general. This was 
explained by the state of micelles in which the size measurements were performed. 
The results are in good agreement as the hydrodynamic sizes measured by DLS 
are known to be larger than the dry state sizes measured by TEM.  
4.8 Buffer Capacity Measurements 
Drugs and nucleic acids have to evade lysosomal degradation in order to 
go to their sites of action in the cell. In the case of siRNAs, the gene silencing 
occurs in the cytoplasm and thus the siRNA has to be released in the cytoplasm 
for necessary action. Buffering capacity is an important measure for polycationic 
vectors that allows endosomal escape of the cargo. The buffering capacity is 
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evaluated by the amount of protons necessary for reducing the pH in the 
endosomal pH range of 7-5.5138. 
 PEI based cationic polymeric vectors have been shown to have optimal 
buffering capacity as a result of having many protonatable amine groups in their 
backbone156. According to the proton sponge hypothesis, amine groups in PEI get 
protonated and increase osmotic pressure in endosomes leading to their 
membrane rupture and release of drug/nucleic acids in cytoplasm157.  
Acid base titrations are perfect evaluators of the buffering capacity. Good 
buffering capacity is indicated by slow, rather than steep change in pH, upon 
addition of the same amount of HCl to polymeric solutions during titration158. 
 As shown in figure 3.11, a sharp drop in pH was seen during acid titration 
of 150 mM NaCl solution (the negative control), which had no buffering capacity. 
On the other hand, all the positive control PEI polymers, as well as SMAPIE-PEI-
N3 and SMAPIE-PEI-Gal micelles exhibited small pH changes with acid addition 
indicating their good buffering capacity. Two inflection points of slow pH changes 
were seen in titration curves of the polymers and the micelles as a result of having 
different types of protonatable amine residues (primary, secondary, and tertiary). 
This was in agreement with previous reports159,160. SMAPIE-PEI-N3 micelles 
showed lower buffer capacity compared to PEI because of the partial azide 
modification in SMAPIE-PEI-N3 polyethylenimine segment, which decreased the 
number of available protonatable amine groups. Another reason is that the 
carboxylic acid groups in SMAPIE could protonate some PEI primary amines into 
ammonium groups through zwitter-ion formation. According to a previous study, 
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ammonium groups can suppress protonation of surrounding amine groups161. On 
the other hand, SMAPIE-PEI-Gal micelles were very similar to PEI polymers and 
better than SMAPIE-PEI-N3 micelles in their buffering capacity. Triazole rings 
conjugating galactosamino PEG5 moieties in SMAPIE-PEI-Gal micelles had amine 
groups which participate in increasing the micelles buffering ability by being 
protonatable at 7-5.5 pH range.  
4.9 Biological evaluation of SMAPIE-PEI-N3 and SMAPEI-PEI-Gal micelles 
4.9.1 Cytotoxicity Assay Using Human Liver Cancer Cells 
Cytotoxicity is one of the most important aspects in the evaluation of non-
viral gene/siRNA vectors composed of cationic polymers for safe gene therapy. 
Cytotoxicity of non-targeted SMAPIE-PEI-N3, and targeted SMAPIE-PEI-Gal 
micelles forming block co-polymers were investigated in Hep G2 cells. PEI 
polymers were studied as controls for comparison.  
As shown in figure 3.12, SMAPIE-PEI-Gal < PEI 10 KDa < SMAPIE-PEI-N3 
< PEI 25 KDa in order of their cytotoxicity and IC50. PEI 25KDa was more cytotoxic  
than PEI I0 KDa due to its higher cationic charge density, which interacts with the 
cell membrane and causes cell necrosis139. In line with previously reported studies, 
galactosamino-PEG5 moieties in SMAPIE-PEI-Gal micelles lead to reduction in 
cytotoxicity by 2-fold  as compared to PEI 10 KDa and by 3-fold  as compared to 
SMAPIE-PEI-N3 micelles due to possible shielding of cationic PEI groups132,150. 
Unexpectedly, SMAPIE-PEI-N3 was more cytotoxic than PEI 10 KDa, but this 
might be explained by the conformation of the cationic groups in the shell of the 
micelles that might arrange in a way that increased their electrostatic interaction 
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with the negatively charged cell membrane and induced more toxicity. However, 
addition of targeting ligand or other functional moieties to SMAPIE-PEI-N3 micelles 
block copolymer can reduce its cytotoxicity as proven in case of SMAPIE-PEI-Gal 
copolymer.  
SMAPIE-PEI-N3 micelles, SMAPIE-PEI-Gal micelles, and PEI 10 KDa 
polymer were complexed with siRNA to form less cytotoxic micelleplexes or 
polyplexes used subsequently in cellular uptake or transfection evaluation 
experiments. The reason for the lesser cytotoxicity is because the negatively 
charged siRNA gets condensed by ionic interaction with a portion of the cationic 
groups in the micelles or PEI 10 KDa polymer, thus decreasing the number of the 
cationic groups available to interact with the cell membrane to cause 
cytotoxicity131,162. Although, cell viability was more than 80% in case of SMAPIE-
PEI-N3, SMAPIE-PEI-Gal, and PEI 10 KDa at concentrations below 20 µg/mL, and 
siRNA condensation should improve the cell viability more, it is important to note 
that the polymers or micelles concentration used in the subsequent in vitro 
experiments was 6.7 µg/mL or lesser depending on the micelle or polymer type. 
As a result, more than 90% cell viability was ensured in all the following in-vitro 
experiments.  
4.9.2 Cellular Uptake Quantification by Flow Cytometry 
Cellular uptake is an ultimate prerequisite for specific siRNA delivery and 
achievement of good transfection efficiency. Naked siRNAs are degraded by 
serum nucleases and have poor cell membrane penetration ability. These major 
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obstacles of diminished stability and poor cellular uptake, ultimately result in 
restricted and inefficient delivery71,163.  
Polycationic vectors have shown promising potentials for resolving the 
siRNA delivery problems. Polycationic vectors such as PEI can electrostatically 
complex siRNA and sequester them from the enzymatic degradation by 
endo/exonucleases. They also improve the siRNA cargo cellular delivery through 
mediating endocytic cellular internalization70. Polycationic vectors functionalized 
with receptor specific targeting ligands help to achieve selective active targeting of 
siRNA therapy to affected tissues that overexpress the complementary ligand 
receptors and thus increase the therapeutic efficiency101,150,164.  
Asialoglycoprotein (ASGP) receptors are among those targetable 
receptors, and are used for targeted therapy of liver cancer.  ASGPRs are c-type 
lectin receptors165 that were found to be over expressed in several human 
neoplastic hepatocytes118 and   hepatocellular carcinoma cell lines including Hep 
G2 and Huh7.5 cells119,120. ASGPRs selectively binds and internalize different 
molecules terminating with carbohydrate residues such as galactose, 
galactosamine, or N- acetylgalactosamine through receptor mediated 
endocytosis121,122.    
Cellular uptake quantification and analysis using flow cytometry was 
conducted to evaluate the siRNA delivery ability as well as (ASGP) receptor 
targeting efficiency of galactosamine targeted SMAPIE-PEI-Gal micelleplexes 
versus the non-targeted SMAPIE-PEI-N3 ones in Hep G2 cells. PEI 10 KDa 
polyplexes were studied as positive transfection control for comparison, while free 
82  
  
siRNA and untreated cells served as negative controls. Micelleplexes or 
polyplexes were formed by complexation of fluorescent FAM-siRNA with SMAPIE-
PEI-Gal, SMAPIE-PEI-N3 polycationic micelles and PEI 10 KDa polycationic 
polymer. 
As illustrated in figure 3.14, statistical analysis of the median fluorescence 
intensities showed that naked siRNA achieved insignificant cellular uptake 
compared to untreated cells. This could be attributed to poor stability and inefficient 
cell penetration of the naked siRNA as mentioned above. On the other hand, 
siRNA condensation with both polycationic micelles and PEI polymer protected the 
siRNA and increased its cellular internalization significantly. Interestingly, cellular 
uptake of non-targeted SMAPIE-PEI-N3 micelleplexes was not significantly 
different from that of PEI 10 KDa polyplexes. One possible explanation is that, 
SMAPIE-PEI-N3 micelleplexes which had PEI chain residues in their micellar 
corona that were not decorated with targeting ligands, entered the cells via the 
same endocytic pathway as PEI 10 KDa polyplexes. It was previously reported that 
PEI polyplexes were taken up by Hep G2 cells through clathrin-mediated 
endocytosis166. On the other hand, galactosamine targeted SMAPIE-PEI-Gal 
micelleplexes showed 0.84 fold higher cellular entry than the non-targeted 
counterparts. In line with earlier studies, SMAPIE-PEI-Gal micelleplexes where 
taken up by Hep G2 cells through receptor mediated endocytosis, since the 
galactosamine targeting ligands bind to the overexpressed ASGPRs facilitating the 
micelleplexes cellular internalization selectively in huge quantities124,125. This 
pathway was further confirmed by the significant decrease in the cellular uptake of 
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SMAPIE-PEI-Gal micelleplexes in the presence of free galactosamine as 
competitive control. The free galactosamine didn’t prevent SMAPIE-PEI-Gal 
micelleplexes internalization completely since it only competed for the ASGP 
receptors (without irreversibly occupying them) thereby decreasing their timely 
availability for SMAPIE-PEI-Gal micelleplexes. The enhanced ASGPRs targeting 
efficiency of SMAPIE-PEI-Gal micelleplexes suggests its potential value for 
selectively targeting hepatocytes for treatment of hepatocellular carcinoma and 
other liver diseases that overexpress the target receptors (ASGPRs). 
4.9.3 Cellular Uptake and Endosomal Escape by Confocal Laser Scanning Microscopy (CLSM) 
Confocal laser scanning microscopy serves as an important tool for 
visualization, imaging and studying of drugs / nucleic acids nanocarriers cellular 
uptake as well as their sub-cellular localization. The process involves the use of 
fluorescent labels for marking the carriers or their cargo and also for 
denoting/marking the necessary cellular compartments.  
Confocal laser scanning microscopy was performed to study the ability of 
both targeted SMAPIE-PEI-Gal and non-targeted SMAPIE-PEI-N3 micelleplexes 
to deliver siRNA to cytoplasm of asialoglycoprotein receptor (ASGPR) positive Hep 
G2 cells as well as the route of cellular uptake. PEI 10 KDa polyplexes were used 
as positive control. ASGPR targeting efficiency of SMAPIE-PEI-Gal micelleplexes 
was evaluated in absence and presence of free galactosamine as competitor 
ligand of ASGPRs.  
Micelleplexes or polyplexes were prepared with FAM-labeled siRNA at N/P 
ratio of 10. The cells nuclei were stained with Hoechst 33342 stain (blue), acidic 
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endosomal compartments with Lyso Tracker Deep Red dye (red), and siRNA was 
labeled with FAM (green).  
As shown in figure 3.15, the sub-cellular localization of the green fluorescent 
siRNA was in the cytoplasm around the blue nucleus or in the red endosomal 
compartments at 22 hours post transfection. The co-localization of siRNA (green) 
and endosomes (red) as denoted by yellow colored regions in the merged images 
indicated that the siRNA complexes underwent cell entry through endocytosis. 
SMAPIE-PEI-N3 micelleplexes and PEI 10 KDa polyplexes most likely entered 
through non-specific endocytosis due to electrostatic interaction of their cationic 
charge with the anionic plasma membrane as noted before71. On the other hand, 
and in concordance with the flow cytometry results, galactosamine targeted 
SMAPIE-PEI-Gal micelleplexes were taken up into Hep G2 cells that overexpress 
ASGPRs primarily via receptor mediated endocytosis. Indeed, the galactosamine 
ASGPRs targeting effect in SMAPIE-PEI-Gal micelleplexes was proven by the 
huge reduction in the micelleplexes uptake with free galactosamine competitor 
presence in the transfection medium as reflected by the lowering of green 
fluorescence intensity (figures 3.15 and 3.16).  
As illustrated in the CLSM images, most of the green siRNA spots were 
present in the cytoplasm compared to very little amount remaining entrapped in 
the endosomes. This was true in the case of targeted SMAPIE-PEI-Gal 
micelleplexes and PEI 10 KDa polyplexes, while for the non-targeted SMAPIE-
PEI-N3 micelleplexes, more portion of the siRNA remained in the endosomes 
compared to that released in the cytoplasm at the same time point. This result 
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could be attributed to the previously found low buffering capacity of SMAPIE-PEI-
N3 micelles versus SMAPIE-PEI-Gal micelles and PEI 10 KDa polymer (figure 
3.11). In line with previous findings70,132,167, the high buffering ability of SMAPIE-
PEI-Gal micelleplexes and PEI 10KDa polyplexes increased their endosomal 
escape, which consequently increased the available siRNA for gene silencing 
through binding to the RNA induced silencing complex (RISC) in the cytoplasm 
causing the required RNA interference. This suggests that SMAPIE-PEI-Gal 
micelleplexes could achieve better transfection efficiency and specific gene 
knockdown than the non-targeted SMAPIE-PEI-N3 micelleplexes.  
4.9.4 Transfection Efficiency and Nrf2 Gene Knockdown by Western Blot analysis 
SMAPIE-PEI-Gal micelleplexes transfection efficiency and ability to deliver 
siRNA to Hep G2 cells in an effective manner was evaluated using western blot 
analysis. Effective siRNA delivery is a prerequisite for achieving efficient gene 
knockdown, which is the ultimate goal of siRNA therapy.  
Nrf2 gene was chosen as target gene for the study due to its established 
role in promoting HCC cells proliferation, invasion, metastasis, and 
chemoresistance, as documented in previous publications49,57,58. Nrf2 
downregulation or inhibition was proven to resensitize HCC cells to many 
anticancer drugs including 5-fluorouracil (5-FU), cisplatin, and doxorubicin57–59. As 
a result, Nrf2 protein is a potential therapeutic target in HCC management.  
SMAPIE-PEI-Gal micelleplexes and PEI 10 KDa polyplexes were prepared 
by complexing Nrf2-siRNA or negative control non-target specific siRNA (NCr-
siRNA) at N/P ratio of 10. PEI 10 KDa was used as positive transfection control, 
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while micelleplexes or polyplexes condensing NCr-siRNA were used as negative 
controls for comparison. Hep G2 cells were chosen for the study as it was reported 
to be positive for Nrf2 expression with Nrf2 main localization in the cytoplasm168. 
Hep G2 cells were transfected for 24 hours with micelleplexes or polyplexes 
containing 50 nM siRNA through reverse transfection technique as Hep G2 cells 
are among the “hard to transfect” cell lines169 and reverse transfection was 
reported to achieve superior results as compared to the traditional transfection 
methodology. The Nrf2 protein half-life was reported to be very short (less than 20 
minutes)170, consequently similar to previous publication, the transfection time in 
the study was set to 24 hours after which immunoblotting was performed for Nrf2 
protein level measurement and gene knockdown assessment171. 
As demonstrated from the results (figure 3.17), after 24 hours of 
transfection, both Nrf2 condensing SMAPIE-PEI-Gal micelleplexes and PEI 10 
KDa polyplexes succeeded to achieve statistically significant (p ˂ 0.05) Nrf2 gene 
knockdown and Nrf2 protein translation interference by around 49% and 27% 
respectively. In line with previously obtained cellular uptake, buffering capacity and 
endosomal escape data, these results confirmed the ability of SMAPIE-PEI-Gal 
micelles to effectively deliver siRNA in HCC cells in effective quantity, with effective 
endosomal escape and high availability for incorporation in the cytoplasmic 
silencing machinery in order to produce efficient gene knockdown. Interestingly, 
SMAPIE-PEI-Gal micelleplexes exhibited statistically significant and superior Nrf2 
gene knockdown when compared with that observed with PEI 10 KDa polyplexes, 
(p ˂ 0.05). This could be explained by the efficient ASGPRs based internalization 
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and targeting ability and the higher cellular uptake of SMAPIE-PEI-Gal 
micelleplexes than PEI 10 KDa polyplexes as illustrated before. In conclusion, 
SMAPIE-PEI-Gal micelles forming block copolymer is a promising vector for 
delivering Nrf2 siRNA, promoting sequence specific gene knockdown in Hep G2 
liver cancer cells. The newly synthesized micelle forming block co-polymer thus 
holds potential to serve as targeted nanocarrier delivery system to counteract the 
chemoresistance of HCCs. 
 
 
 
 
 
 
 
 
 
 
88  
  
SUMMARY 
In this study, we successfully synthesized micellar polymeric nanodelivery 
system that can be used as multifunctional modular platform in cancer therapy 
and/or diagnosis. The micelles (SMAPIE-PEI-N3) were constructed from 
poly(Styrene-co-maleic anhydride, partial iso-octyl ester) co-polymeric chain 
(SMAPIE) grafted to branched polyethylenimine10 KDa polymeric chain (PEI) in 
which primary amine groups were partially modified into azide groups (N3). 
Different targeting ligands and imaging agents can be conjugated to SMAPIE-PEI-
N3 micelles simultaneously or individually by applying copper free “click” chemistry 
strategies, for targeting various resistant and metastatic cancers overexpressing 
complementary receptors. In this study, as a proof-of-concept, galactosamine 
decorated micelles (SMAPIE-PEI-Gal) were synthesized to efficiently target 
asialoglycoprotein (ASGP) receptors overexpressed in liver cancers.  
The successful synthesis of targeted and non-targeted micelles forming 
block copolymers was confirmed by 1H NMR and FT/IR. The relative molecular 
weight and PEI composition of the micelles were determined using size exclusion 
chromatography and copper chelation assay, respectively. Critical micelle 
concentration of SMAPIE-PEI-N3 micelles was determined using pyrene as a 
fluorescent probe and was found to be as low as 0.0112 mg/ml, indicating its 
potential to be of high stability even on dilution in vivo. In terms of the siRNA 
condensation ability evaluated by the SYBER Gold fluorescent dye, SMAPIE-PEI-
Gal micelles were found to be of more efficient siRNA condensation capacity than 
SMAPIE-PEI-N3 micelles at N/P ratio lower than 10. The hydrodynamic size of 
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SMAPIE-PEI-N3 and SMAPIE-PEI-Gal micelles was around 160 nm and 240 nm 
respectively with moderate polydispersity index, but they had high zeta potential 
of about 40 mV. On the other hand, SMAPIE-PEI-N3 and SMAPIE-PEI-Gal 
micelleplexes exhibited decreasing pattern of hydrodynamic size with increasing 
N/P ratio and achieved more complete siRNA condensation. The size of 200 nm 
at N/P ratio of 10 is optimum for EPR mediated passive accumulation in cancer 
tissues. SMAPIE-PEI-N3 and SMAPIE-PEI-Gal micelleplexes zeta potential 
decreased as a consequence of siRNA condensation as compared to the highly 
cationic plain micelles. Transmission electron microscopy (TEM) images 
demonstrated the spherical core/shell morphology of both the plain micelles and 
the siRNA complexing micelleplexes. In terms of buffering capacity and endosomal 
escape potential, SMAPIE-PEI-Gal micelles were of high buffer capacity 
comparable to that of PEI polymers. However it was found that SMAPIE-PEI-Gal 
was superior to SMAPIE-PEI-N3 micelles in buffering ability. Cytotoxicity 
evaluation of both targeted and non-targeted micelles in Hep G2 cells showed 
more than 80% cell viability at concentrations below 20 µg/ml, however much 
better cell viability was observed in the transfection experiments as only a total 
polymer concentration of 6.7 µg/ml or lesser was used/needed.  
Cellular uptake of SMAPIE-PEI-Gal micelleplexes via the ASGP receptor 
mediated endocytosis was confirmed by the free galactosamine competition assay 
results. In contrast to galactosamine targeted SMAPIE-PEI-Gal micelleplexes, 
cellular uptake of non-targeted SMAPIE-PEI-N3 micelleplexes and PEI polyplexes 
could be attributed to the cationic charge mediated non-specific endocytosis 
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demonstrated in the co-localization of some SMAPIE-PEI-N3 micelleplexes and 
PEI polyplexes with endosomes, as illustrated by CLSM. Quantification of cellular 
uptake of PEI 10 KDa polyplexes, SMAPIE-PEI-N3 micelleplexes, and SMAPIE-
PEI-Gal micelleplexes in Hep G2 cells by flow cytometry showed statistically 
significant and superior cellular internalization by SMAPIE-PEI-Gal micelleplexes, 
(p ˂ 0.01). Indeed, SMAPIE-PEI-Gal micelleplexes cellular uptake was higher than 
that of SMAPIE-PEI-N3 micelleplexes and PEI 10 KDa polyplexes by 0.84 and 1.2 
folds respectively, due to the overexpression of ASGPRs in HCC cells. 
 In conclusion, as noted from all the above data, SMAPIE-PEI-Gal micelles 
forming block copolymer showed better physical and biological characteristics than 
SMAPIE-PEI-N3 copolymer. As a result, SMAPIE-PEI-Gal micelles were chosen 
to further study their siRNA transfection efficiency and ability to achieve effective 
gene knockdown. As expected, SMAPIE-PEI-Gal micelleplexes successfully 
mediated significant 0.49 fold Nrf2 gene knockdown in ASGPRs overexpressing 
Hep G2 cells. The Nrf2 gene knockdown was 21% higher than the one mediated 
by the positive transfection control PEI 10 KDa polyplexes at statistical significance 
of (p ˂ 0.05). These results emphasize that SMAPIE-PEI-Gal is a promising 
candidate for siRNA delivery to HCC. Its application to knockdown Nrf2 gene, can 
counteract the “dark side” of Nrf2 in HCC, where it decreases HCC cells survival 
and chemoresistance, warranting further investigations. 
In future experiments, SMAPIE-PEI-Gal micelles can be studied both in vitro 
and in vivo for co-delivery of chemotherapeutic agent and Nrf2 or MDR1 siRNA to 
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overcome chemoresistance and achieve synergistic control on tumor growth in 
HCC. 
The scope of study could be extended by employing SMAPIE-PEI-N3 as a 
modular micellar block co-polymer through attachment of different targeting 
ligands or imaging agents and studying the potential of the so-formed 
micelles/micelleplexes to achieve targeted therapy of different types of cancer. 
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ABSTRACT 
TARGETED DELIVERY OF NRF2 SIRNA USING MODULAR POLYMERIC MICELLAR NANODELIVERY SYSTEM FOR EFFICIENT TARGET GENE KNOCKDOWN IN HEPATOCELLULAR CARCINOMA 
by 
SHAIMAA YOUSEF 
August 2016 
Advisor: Dr. Arun Iyer 
Major: Pharmaceutical Sciences (Pharmaceutics) 
Degree: Master of Sciences 
Tumor selective drug delivery as well as chemotherapy associated multi 
drug resistance (MDR) pose tremendous hurdles for effective cancer therapy. In 
this regard, designing multifunctional nanocarriers loaded with drug/gene payloads 
and engineered with tumor targeting ligands can serve as a modular platform for 
targeted drug/gene delivery. In this study we undertook the synthesis of a self-
assembling block copolymer constructed using poly(styrene-co-maleic anhydride, 
partial iso-octyl ester) (SMAPIE) and branched polyethylenimine (PEI) as building 
blocks and evaluated its micelle forming ability, siRNA complexation and siRNA 
delivery potentials. In addition, we engineered galactosamine decorated 
nanomicelles using modular “click” chemistry based approaches for evaluating the 
targeted delivery of Nrf2 siRNA to Hep G2 liver cancer cells overexpressing 
asialoglycoprotein receptors (ASGPRs). Our results demonstrate that the 
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galactosamine decorated nanocarriers could effectively deliver Nrf2 siRNA into 
Hep G2 liver cancer cells resulting in efficient target gene knockdown, evincing its 
potential for targeted liver cancer therapy.
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